[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 31836
1. Mitchell G, Girgis A, Jiwa M, Sibbritt D, Burridge L: A GP Caregiver Needs Toolkit versus usual care in the management of the needs of caregivers of patients with advanced cancer: a randomized controlled trial. Trials; 2010;11:115
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A GP Caregiver Needs Toolkit versus usual care in the management of the needs of caregivers of patients with advanced cancer: a randomized controlled trial.
  • BACKGROUND: Caring for a person with progressive cancer creates challenges for caregivers.
  • This paper outlines a study protocol aimed at developing and evaluating the effectiveness of a general practice-based intervention to better meet the needs of caregivers of patients with advanced cancer.
  • METHODS/DESIGN: Two hundred and sixty caregivers will be randomised into each of two arms of the intervention (520 participants in total) through patients with advanced cancer attending medical and radiation oncology outpatient clinics at two tertiary hospital sites.
  • DISCUSSION: This study will determine whether systematic assessment of caregiver needs supported by caregiver-specific information for General Practitioners is effective in alleviating the unmet needs experienced by caregivers caring for patients with advanced cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pain Symptom Manage. 1999 Jun;17(6):418-28 [10388247.001]
  • [Cites] J Palliat Med. 2003 Dec;6(6):911-8 [14733683.001]
  • [Cites] Palliat Med. 2005 Oct;19(7):551-5 [16295288.001]
  • [Cites] Eur J Cancer Care (Engl). 2006 May;15(2):163-71 [16643264.001]
  • [Cites] Palliat Med. 2008 Dec;22(8):904-12 [18772208.001]
  • [Cites] Palliat Med. 2008 Dec;22(8):956-64 [18952754.001]
  • [Cites] J Eval Clin Pract. 2009 Aug;15(4):602-6 [19522727.001]
  • [Cites] Psychooncology. 2010 Jul;19(7):726-33 [19777532.001]
  • [Cites] Palliat Med. 2003 Jan;17(1):63-74 [12597468.001]
  • [Cites] Palliat Med. 2003 Jan;17(1):27-39 [12597463.001]
  • [Cites] J Pain Symptom Manage. 2002 Aug;24(2):91-6 [12231124.001]
  • [Cites] Hematol Oncol Clin North Am. 2002 Jun;16(3):745-62, xi [12170579.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3219-25 [11432889.001]
  • [Cites] Cancer. 2000 Jan 1;88(1):217-25 [10618626.001]
  • [Cites] Palliat Med. 1994;8(3):183-96 [7952369.001]
  • [Cites] Acta Psychiatr Scand. 1983 Jun;67(6):361-70 [6880820.001]
  • [Cites] CMAJ. 2004 Jun 8;170(12):1795-801 [15184333.001]
  • [Cites] J Palliat Med. 2004 Feb;7(1):19-25 [15008126.001]
  • [Cites] Psychooncology. 2011 Apr;20(4):387-93 [20878835.001]
  • [Cites] Med Care. 2003 Aug;41(8):992-1001 [12886178.001]
  • [Cites] Psychooncology. 2005 Jun;14(6):492-502 [15452896.001]
  • (PMID = 21114863.001).
  • [ISSN] 1745-6215
  • [Journal-full-title] Trials
  • [ISO-abbreviation] Trials
  • [Language] eng
  • [Databank-accession-numbers] ISRCTN/ ISRCTN43614355
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3009964
  •  go-up   go-down


2. Macciò A, Madeddu C, Gramignano G, Mulas C, Sanna E, Mantovani G: Efficacy and safety of oral lactoferrin supplementation in combination with rHuEPO-beta for the treatment of anemia in advanced cancer patients undergoing chemotherapy: open-label, randomized controlled study. Oncologist; 2010;15(8):894-902
MedlinePlus Health Information. consumer health - Anemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of oral lactoferrin supplementation in combination with rHuEPO-beta for the treatment of anemia in advanced cancer patients undergoing chemotherapy: open-label, randomized controlled study.
  • Advanced-stage cancer patients often suffer from anemia that closely resembles the anemia of chronic inflammatory diseases characterized by specific changes in iron homeostasis and absorption. i.v. iron improves the efficacy of recombinant human erythropoietin (rHuEPO) in anemic cancer patients undergoing chemotherapy.
  • We report the results of an open-label, randomized, prospective trial aimed at testing the efficacy and safety of treatment with oral lactoferrin versus i.v. iron, both combined with rHuEPO, for the treatment of anemia in a population of 148 advanced cancer patients undergoing chemotherapy.
  • In conclusion, these results show similar efficacy for oral lactoferrin and for i.v. iron, combined with rHuEPO, for the treatment of anemia in advanced cancer patients undergoing chemotherapy.

  • Genetic Alliance. consumer health - Anemia.
  • Genetic Alliance. consumer health - Oral cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2009 May 2;373(9674):1532-42 [19410717.001]
  • [Cites] Biochem Pharmacol. 2009 May 15;77(10):1572-9 [19174153.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2840-6 [10561360.001]
  • [Cites] Cancer. 2001 Jun 15;91(12):2214-21 [11413508.001]
  • [Cites] Haematologica. 2002 Nov;87(11):1209-21 [12414352.001]
  • [Cites] Blood. 2003 Aug 1;102(3):783-8 [12663437.001]
  • [Cites] Lancet. 2003 Oct 18;362(9392):1255-60 [14575968.001]
  • [Cites] Semin Oncol. 2003 Oct;30(5 Suppl 16):174-84 [14613039.001]
  • [Cites] Am J Med. 2004 Apr 5;116 Suppl 7A:11S-26S [15050883.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1301-7 [15051778.001]
  • [Cites] J Clin Invest. 2004 May;113(9):1251-3 [15124013.001]
  • [Cites] Int J Cancer. 2004 Sep 1;111(3):398-403 [15221967.001]
  • [Cites] Biometals. 2004 Jun;17(3):209-16 [15222467.001]
  • [Cites] N Engl J Med. 1990 Jun 14;322(24):1689-92 [2342534.001]
  • [Cites] Blood. 1992 Oct 1;80(7):1639-47 [1391934.001]
  • [Cites] J Natl Cancer Inst. 1999 Oct 6;91(19):1616-34 [10511589.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):1011-23 [15758012.001]
  • [Cites] Blood. 2005 Jul 1;106(1):362-7 [15774616.001]
  • [Cites] Oncologist. 2005 Jun-Jul;10(6):438-48 [15967837.001]
  • [Cites] Nat Rev Cancer. 2005 Jul;5(7):543-55 [15965494.001]
  • [Cites] Stem Cells Dev. 2005 Oct;14(5):548-55 [16305339.001]
  • [Cites] Am J Clin Nutr. 2006 Feb;83(2):305-9 [16469988.001]
  • [Cites] Oncologist. 2007 Feb;12(2):231-42 [17296819.001]
  • [Cites] Clin Cancer Res. 2007 Mar 1;13(5):1601-10 [17332307.001]
  • [Cites] Lancet. 2007 May 5;369(9572):1502-4 [17482969.001]
  • [Cites] J Clin Oncol. 2008 Jan 1;26(1):132-49 [17954713.001]
  • [Cites] JAMA. 2008 Feb 27;299(8):914-24 [18314434.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1611-8 [18375890.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1619-25 [18375891.001]
  • [Cites] J Natl Compr Canc Netw. 2008 Jul;6(6):536-64 [18597709.001]
  • [Cites] Cancer. 2008 Sep 15;113(6):1480-8 [18642348.001]
  • [Cites] Int J Antimicrob Agents. 2009 Apr;33(4):301.e1-8 [18842395.001]
  • [Cites] Semin Arthritis Rheum. 2009 Apr;38(5):382-8 [18336871.001]
  • [Cites] J Clin Oncol. 2009 Sep 1;27(25):4217-26 [19636005.001]
  • (PMID = 20647390.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ferric Compounds; 0 / Hemoglobins; 0 / Recombinant Proteins; 11096-26-7 / Erythropoietin; 88088-23-7 / ferric gluconate; EC 3.4.21.- / Lactoferrin
  • [Other-IDs] NLM/ PMC3228020
  •  go-up   go-down


3. Kadan-Lottick NS, Vanderwerker LC, Block SD, Zhang B, Prigerson HG: Psychiatric disorders and mental health service use in patients with advanced cancer: a report from the coping with cancer study. Cancer; 2005 Dec 15;104(12):2872-81
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Psychiatric disorders and mental health service use in patients with advanced cancer: a report from the coping with cancer study.
  • BACKGROUND: Psychological morbidity has been proposed as a source of distress in cancer patients.
  • 1) determine the prevalence of diagnosable psychiatric illnesses, and 2) describe the mental health services received and predictors of service utilization in patients with advanced cancer.
  • METHODS: This was a cross-sectional, multi-institutional study of 251 eligible patients with advanced cancer.
  • RESULTS: Overall, 12% met criteria for a major psychiatric condition and 28% had accessed a mental health intervention for a psychiatric illness since the cancer diagnosis.
  • Cancer patients who had discussed psychological concerns with mental health staff (odds ratio [OR] = 19.2; 95% confidence interval [95% CI], 8.90-41.50) and non-Hispanic white patients (OR = 2.7; 95% CI, 1.01-7.43) were more likely to receive mental health services in adjusted analysis.
  • CONCLUSIONS: Advanced cancer patients experience major psychiatric disorders at a prevalence similar to the general population, but affected individuals have a low rate of utilizing mental health services.

  • MedlinePlus Health Information. consumer health - Cancer--Living with Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • [Cites] JAMA. 1983 Feb 11;249(6):751-7 [6823028.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6899-907 [16129849.001]
  • [Cites] J Clin Oncol. 1985 Nov;3(11):1553-60 [4056846.001]
  • [Cites] Ann Intern Med. 1987 Oct;107(4):481-5 [3631786.001]
  • [Cites] Lancet. 1999 Oct 16;354(9187):1331-6 [10533861.001]
  • [Cites] Ann Intern Med. 2000 Feb 1;132(3):209-18 [10651602.001]
  • [Cites] Palliat Med. 1999 Jul;13(4):353-4 [10659105.001]
  • [Cites] Cancer. 2000 May 15;88(10):2398-424 [10820364.001]
  • [Cites] JAMA. 2000 Nov 15;284(19):2518-21 [11074786.001]
  • [Cites] JAMA. 2000 Dec 13;284(22):2907-11 [11147988.001]
  • [Cites] Ethn Dis. 2001 Winter;11(1):97-106 [11289258.001]
  • [Cites] Patient Educ Couns. 2001 Dec 1;45(3):195-8 [11722855.001]
  • [Cites] J Clin Psychiatry. 2001;62 Suppl 8:64-7 [12108825.001]
  • [Cites] Cancer. 2002 Jun 1;94(11):3006-15 [12115391.001]
  • [Cites] Hematol Oncol Clin North Am. 2002 Jun;16(3):671-700 [12170575.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2754-9 [12860955.001]
  • [Cites] Am J Hematol. 2003 Nov;74(3):224 [14587060.001]
  • [Cites] Semin Clin Neuropsychiatry. 2003 Oct;8(4):241-52 [14613051.001]
  • [Cites] Jpn J Clin Oncol. 2003 Oct;33(10):538-40 [14623924.001]
  • [Cites] Gen Hosp Psychiatry. 2004 Mar-Apr;26(2):121-8 [15038929.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1957-65 [15143090.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Jun;130(6):327-33 [15007642.001]
  • [Cites] J Natl Cancer Inst Monogr. 2004;(32):9-16 [15263035.001]
  • [Cites] J Natl Cancer Inst Monogr. 2004;(32):32-9 [15263039.001]
  • [Cites] J Natl Cancer Inst Monogr. 2004;(32):57-71 [15263042.001]
  • [Cites] J Natl Cancer Inst Monogr. 2004;(32):80-92 [15263046.001]
  • [Cites] J Natl Cancer Inst Monogr. 2004;(32):127-35 [15263054.001]
  • [Cites] Br J Cancer. 1991 Aug;64(2):349-52 [1892762.001]
  • [Cites] Int J Psychiatry Med. 1991;21(2):149-55 [1894454.001]
  • [Cites] Psychosomatics. 1991 Fall;32(4):420-5 [1961856.001]
  • [Cites] Arch Gen Psychiatry. 1992 Aug;49(8):630-6 [1637253.001]
  • [Cites] Eur J Cancer. 1993;29A(4):524-7 [8435204.001]
  • [Cites] Psychosomatics. 1993 May-Jun;34(3):208-21 [8493302.001]
  • [Cites] Palliat Med. 1993;7(3):213-8 [8261189.001]
  • [Cites] J Affect Disord. 1993 Oct-Nov;29(2-3):77-84 [8300980.001]
  • [Cites] Qual Life Res. 1994 Jun;3(3):183-9 [7920492.001]
  • [Cites] J Pain Symptom Manage. 1995 Feb;10(2):131-41 [7730685.001]
  • [Cites] Am J Psychiatry. 1995 Aug;152(8):1185-91 [7625468.001]
  • [Cites] N Engl J Med. 1996 Jul 18;335(3):172-8 [8657216.001]
  • [Cites] Soc Sci Med. 1996 Jun;42(11):1511-9 [8771634.001]
  • [Cites] Clin Geriatr Med. 1996 May;12(2):329-47 [8799351.001]
  • [Cites] Am J Psychiatry. 1997 Dec;154(12):1734-40 [9396954.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1594-600 [9552071.001]
  • [Cites] Psychosomatics. 1998 Jul-Aug;39(4):366-70 [9691706.001]
  • [Cites] Oncol Nurs Forum. 1999 Apr;26(3):593-9 [10214600.001]
  • [Cites] Palliat Med. 1999 Jan;13(1):45-50 [10320875.001]
  • [Cites] Br J Cancer. 1999 May;80(5-6):766-74 [10360654.001]
  • [Cites] Support Care Cancer. 2004 Sep;12(9):657-62 [15185134.001]
  • [Cites] Support Care Cancer. 2004 Dec;12(12):864-70 [15480816.001]
  • [Cites] Cancer. 1984 May 15;53(10 Suppl):2243-9 [6704912.001]
  • (PMID = 16284994.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA106370; United States / NCRR NIH HHS / RR / K12 RR017594; United States / NIA NIH HHS / AG / P30AG21342; United States / NIMH NIH HHS / MH / MH63892; United States / NCRR NIH HHS / RR / K12RR17594; United States / NIA NIH HHS / AG / P30 AG021342; United States / NIMH NIH HHS / MH / MH56529; United States / NCI NIH HHS / CA / R01 CA106370; United States / NIMH NIH HHS / MH / R01 MH063892
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS8305; NLM/ PMC1459283
  •  go-up   go-down


Advertisement
4. Loprinzi CL, Levitt R, Barton DL, Sloan JA, Atherton PJ, Smith DJ, Dakhil SR, Moore DF Jr, Krook JE, Rowland KM Jr, Mazurczak MA, Berg AR, Kim GP, North Central Cancer Treatment Group: Evaluation of shark cartilage in patients with advanced cancer: a North Central Cancer Treatment Group trial. Cancer; 2005 Jul 1;104(1):176-82
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of shark cartilage in patients with advanced cancer: a North Central Cancer Treatment Group trial.
  • The basis for this popularity is the claim that sharks rarely get cancer because of the high proportion of cartilage in the shark's body.
  • Therefore, a clinical trial was conducted to look at the impact of shark cartilage in patients with advanced cancer.
  • The primary goal of this trial was to determine whether a shark cartilage product improved overall survival for patients with advanced cancer who were getting standard care.
  • CONCLUSION: This trial was unable to demonstrate any suggestion of efficacy for this shark cartilage product in patients with advanced cancer.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Complementary and Integrative Medicine.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15912493.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-25224; United States / NCI NIH HHS / CA / CA-35101; United States / NCI NIH HHS / CA / CA-35103; United States / NCI NIH HHS / CA / CA-35113; United States / NCI NIH HHS / CA / CA-35195; United States / NCI NIH HHS / CA / CA-35269; United States / NCI NIH HHS / CA / CA-35272; United States / NCI NIH HHS / CA / CA-35448; United States / NCI NIH HHS / CA / CA-37404; United States / NCI NIH HHS / CA / CA-37417; United States / NCI NIH HHS / CA / CA-52352; United States / NCI NIH HHS / CA / CA-60276; United States / NCI NIH HHS / CA / CA-63848; United States / NCI NIH HHS / CA / CA-63849
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Placebos; 0 / Tissue Extracts
  •  go-up   go-down


5. Gagnon B, Low G, Schreier G: Methylphenidate hydrochloride improves cognitive function in patients with advanced cancer and hypoactive delirium: a prospective clinical study. J Psychiatry Neurosci; 2005 Mar;30(2):100-7
Hazardous Substances Data Bank. METHYLPHENIDATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylphenidate hydrochloride improves cognitive function in patients with advanced cancer and hypoactive delirium: a prospective clinical study.
  • OBJECTIVE: To investigate the clinical improvement observed in patients with advanced cancer and hypoactive delirium after the administration of methylphenidate hydrochloride.
  • METHODS: Fourteen patients with advanced cancer and hypoactive delirium were seen between March 1999 and August 2000 at the Palliative Care Day Hospital and the inpatient Tertiary Palliative Care Unit of Montreal General Hospital, Montreal.
  • CONCLUSIONS: Hypoactive delirium that cannot be explained by an underlying cause (metabolic or drug-induced) in patients with advanced cancer appears to be a specific syndrome that could be improved by the administration of methylphenidate.

  • MedlinePlus Health Information. consumer health - Cancer--Living with Cancer.
  • MedlinePlus Health Information. consumer health - Delirium.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Intern Med. 2000 Mar 27;160(6):786-94 [10737278.001]
  • [Cites] Rinsho Shinkeigaku. 1999 May;39(5):555-9 [10424149.001]
  • [Cites] Brain. 2000 Jul;123 ( Pt 7):1481-94 [10869059.001]
  • [Cites] Mayo Clin Proc. 2000 Jul;75(7):711-21 [10907387.001]
  • [Cites] J Pain Symptom Manage. 2000 Jun;19(6):412-26 [10908822.001]
  • [Cites] Eur J Nucl Med. 2000 Oct;27(10):1518-24 [11083541.001]
  • [Cites] J Neurosci. 2001 Feb 15;21(4):1413-9 [11160413.001]
  • [Cites] Am J Hosp Palliat Care. 2001 Nov-Dec;18(6):403-7 [11712722.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):335-9 [11773187.001]
  • [Cites] J Neurosci. 2002 Oct 1;22(19):8705-10 [12351745.001]
  • [Cites] Ann Nucl Med. 2002 Dec;16(8):527-31 [12593417.001]
  • [Cites] Neurosci Biobehav Rev. 2003 Nov;27(7):615-21 [14624806.001]
  • [Cites] J Psychiatr Res. 1975 Nov;12(3):189-98 [1202204.001]
  • [Cites] Can J Psychiatry. 1984 Feb;29(1):46-9 [6704886.001]
  • [Cites] Head Neck Surg. 1986 Mar-Apr;8(4):296-300 [3744858.001]
  • [Cites] N Engl J Med. 1989 Mar 2;320(9):578-82 [2644535.001]
  • [Cites] J Pain Symptom Manage. 1989 Mar;4(1):3-6 [2703735.001]
  • [Cites] Am J Psychiatry. 1990 Jan;147(1):22-30 [2403472.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1990 Dec;53(12):1084-8 [1963440.001]
  • [Cites] Support Care Cancer. 1995 Mar;3(2):135-8 [7539701.001]
  • [Cites] Int J Psychiatry Med. 1995;25(1):1-19 [7649714.001]
  • [Cites] Int J Psychiatry Med. 1995;25(1):53-67 [7649718.001]
  • [Cites] Psychosomatics. 1995 Sep-Oct;36(5):471-9 [7568655.001]
  • [Cites] J Neuropsychiatry Clin Neurosci. 1995 Summer;7(3):347-50 [7580196.001]
  • [Cites] Psychosomatics. 1996 Jan-Feb;37(1):57-62 [8600496.001]
  • [Cites] JAMA. 1996 Mar 20;275(11):852-7 [8596223.001]
  • [Cites] Psychiatr Clin North Am. 1996 Sep;19(3):515-47 [8856815.001]
  • [Cites] Drug Saf. 1996 Oct;15(4):291-301 [8905254.001]
  • [Cites] Semin Oncol. 1997 Jun;24(3):318-28 [9208887.001]
  • [Cites] Brain. 1997 Jun;120 ( Pt 6):923-8 [9217677.001]
  • [Cites] Pathologe. 1997 Sep;18(5):406-10 [9432678.001]
  • [Cites] Neuropediatrics. 1998 Jun;29(3):159-62 [9706628.001]
  • [Cites] Arch Phys Med Rehabil. 1998 Sep;79(9):1047-50 [9749682.001]
  • [Cites] J Pain Symptom Manage. 1998 Sep;16(3):193-8 [9769622.001]
  • [Cites] Rev Neurol (Paris). 1998 Jul;154(6-7):539-41 [9773088.001]
  • [Cites] J Neurol. 1998 Nov;245(11):695-708 [9808237.001]
  • [Cites] N Engl J Med. 1999 Jun 10;340(23):1788-95 [10362822.001]
  • [Cites] J Formos Med Assoc. 1999 May;98(5):368-71 [10420707.001]
  • [Cites] Support Care Cancer. 2000 Mar;8(2):134-7 [10739361.001]
  • (PMID = 15798785.001).
  • [ISSN] 1180-4882
  • [Journal-full-title] Journal of psychiatry & neuroscience : JPN
  • [ISO-abbreviation] J Psychiatry Neurosci
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Central Nervous System Stimulants; 207ZZ9QZ49 / Methylphenidate
  • [Other-IDs] NLM/ PMC551162
  •  go-up   go-down


6. Kutner JS, Smith MC, Corbin L, Hemphill L, Benton K, Mellis BK, Beaty B, Felton S, Yamashita TE, Bryant LL, Fairclough DL: Massage therapy versus simple touch to improve pain and mood in patients with advanced cancer: a randomized trial. Ann Intern Med; 2008 Sep 16;149(6):369-79
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Massage therapy versus simple touch to improve pain and mood in patients with advanced cancer: a randomized trial.
  • OBJECTIVE: To evaluate the efficacy of massage for decreasing pain and symptom distress and improving quality of life among persons with advanced cancer.
  • PATIENTS: 380 adults with advanced cancer who were experiencing moderate-to-severe pain; 90% were enrolled in hospice.
  • The generalizability to all patients with advanced cancer is uncertain.
  • CONCLUSION: Massage may have immediately beneficial effects on pain and mood among patients with advanced cancer.

  • MedlinePlus Health Information. consumer health - Pain.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Nurs. 2000 Oct;23(5):327-36 [11037952.001]
  • [Cites] AACN Clin Issues. 2000 Feb;11(1):77-96 [11040555.001]
  • [Cites] Cancer. 2000 Oct 15;89(8):1854-65 [11042583.001]
  • [Cites] J Pain Symptom Manage. 2000 Nov;20(5):374-87 [11068159.001]
  • [Cites] Stat Med. 2001 Apr 15;20(7):1009-21 [11276032.001]
  • [Cites] Hosp J. 2000;15(3):31-53 [11315685.001]
  • [Cites] Emerg Med J. 2001 May;18(3):205-7 [11354213.001]
  • [Cites] J Pain Symptom Manage. 2001 Jun;21(6):473-80 [11397605.001]
  • [Cites] Cancer Nurs. 2001 Jun;24(3):180-4 [11409061.001]
  • [Cites] Palliat Med. 2001 Sep;15(5):363-71 [11591087.001]
  • [Cites] Eur J Pharmacol. 2001 Oct 19;429(1-3):1-11 [11698022.001]
  • [Cites] Complement Ther Nurs Midwifery. 2000 Nov;6(4):169-75 [11858299.001]
  • [Cites] J Palliat Med. 2002 Jun;5(3):397-406 [12133244.001]
  • [Cites] Palliat Med. 2003 Jun;17(4):300-7 [12822844.001]
  • [Cites] J Pain. 2003 Sep;4(7):407-14 [14622683.001]
  • [Cites] Integr Cancer Ther. 2003 Dec;2(4):332-44 [14713325.001]
  • [Cites] Palliat Med. 2004 Mar;18(2):87-92 [15046404.001]
  • [Cites] Cochrane Database Syst Rev. 2004;(2):CD002287 [15106172.001]
  • [Cites] J Psychosom Res. 2004 Jul;57(1):45-52 [15256294.001]
  • [Cites] J Palliat Med. 2004 Jun;7(3):405-7 [15265348.001]
  • [Cites] Nurs Res. 1986 Mar-Apr;35(2):101-6 [3633503.001]
  • [Cites] Cancer. 1987 Sep 1;60(5):1151-8 [3300951.001]
  • [Cites] World Health Organ Tech Rep Ser. 1990;804:1-75 [1702248.001]
  • [Cites] Holist Nurs Pract. 1991 Oct;6(1):24-31 [1918182.001]
  • [Cites] Cancer Nurs. 1993 Apr;16(2):93-101 [8477405.001]
  • [Cites] Ann Acad Med Singapore. 1994 Mar;23(2):129-38 [8080219.001]
  • [Cites] Qual Life Res. 1994 Jun;3(3):183-9 [7920492.001]
  • [Cites] Eur J Cancer. 1994;30A(9):1326-36 [7999421.001]
  • [Cites] Pain. 1995 May;61(2):277-84 [7659438.001]
  • [Cites] Ann Emerg Med. 1996 Apr;27(4):485-9 [8604867.001]
  • [Cites] J Pain Symptom Manage. 1996 Oct;12(4):209-20 [8898504.001]
  • [Cites] J Pain Symptom Manage. 1996 Nov;12(5):273-82 [8942122.001]
  • [Cites] Neurology. 1997 Feb;48(2):332-8 [9040716.001]
  • [Cites] Palliat Med. 1997 Jan;11(1):3-20 [9068681.001]
  • [Cites] J Pain Symptom Manage. 1997 May;13(5):254-61 [9185430.001]
  • [Cites] Cancer. 1998 Jul 1;83(1):173-9 [9655308.001]
  • [Cites] Support Care Cancer. 1998 Nov;6(6):539-41 [9833305.001]
  • [Cites] Am Psychol. 1998 Dec;53(12):1270-81 [9872050.001]
  • [Cites] JAMA. 1999 Jan 13;281(2):163-8 [9917120.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):361-70 [10458255.001]
  • [Cites] Cancer Invest. 2004;22(4):526-36 [15565810.001]
  • [Cites] Cancer Invest. 2004;22(5):678-87 [15581048.001]
  • [Cites] Cancer Control. 2005 Jul;12(3):186-95 [16062166.001]
  • [Cites] Palliat Support Care. 2003 Sep;1(3):231-7 [16594423.001]
  • [Cites] J Holist Nurs. 2006 Sep;24(3):152-61 [16880409.001]
  • [Cites] Clin Nurs Res. 2007 May;16(2):85-99; discussion 100-2 [17452429.001]
  • [Cites] J Pain Symptom Manage. 2007 Sep;34(3):227-36 [17572055.001]
  • [Cites] Health Qual Life Outcomes. 2007;5:51 [17683554.001]
  • [Cites] Ann Intern Med. 2008 Feb 19;148(4):W60-6 [18283201.001]
  • [Cites] Ann Intern Med. 2008 Feb 19;148(4):295-309 [18283207.001]
  • [Cites] J Soc Integr Oncol. 2008 Winter;6(1):19-28 [18302907.001]
  • [Cites] J Soc Integr Oncol. 2007 Fall;5(4):139-46 [19087757.001]
  • [Cites] Pain. 1999 May;81(1-2):129-34 [10353500.001]
  • [Cites] J Pain Symptom Manage. 1999 Jul;18(1):9-16 [10439568.001]
  • [Cites] J Pain Symptom Manage. 2004 Sep;28(3):244-9 [15336336.001]
  • [Cites] ANS Adv Nurs Sci. 1982 Jul;4(4):44-61 [6808905.001]
  • [Cites] ANS Adv Nurs Sci. 1984 Jan;6(2):42-9 [6322674.001]
  • [Cites] Lancet. 1985 May 25;1(8439):1204-6 [2860399.001]
  • [Cites] BMJ. 2000 Feb 19;320(7233):513-4 [10678876.001]
  • [Cites] Cancer. 2000 Sep 1;89(5):1162-71 [10964347.001]
  • [SummaryForPatientsIn] Ann Intern Med. 2008 Sep 16;149(6):I38 [18794554.001]
  • (PMID = 18794556.001).
  • [ISSN] 1539-3704
  • [Journal-full-title] Annals of internal medicine
  • [ISO-abbreviation] Ann. Intern. Med.
  • [Language] ENG
  • [Grant] United States / NCCIH NIH HHS / AT / 1R01AT0100601A2; United States / NCCIH NIH HHS / AT / R01 AT001006; United States / NCCIH NIH HHS / AT / AT001006-02; United States / NCCIH NIH HHS / AT / R01 AT001006-01A2; United States / NCCIH NIH HHS / AT / AT001006-03; United States / NCCIH NIH HHS / AT / R01 AT001006-03; United States / NCCIH NIH HHS / AT / AT001006-01A2; United States / NCCIH NIH HHS / AT / R01 AT001006-02
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS65966; NLM/ PMC2631433
  •  go-up   go-down


7. Torres-Vigil I, Aday LA, Reyes-Gibby C, De Lima L, Herrera AP, Mendoza T, Cleeland CS: Health care providers' assessments of the quality of advanced-cancer care in Latin American medical institutions: a comparison of predictors in five countries: Argentina, Brazil, Cuba, Mexico, and Peru. J Pain Palliat Care Pharmacother; 2008;22(1):7-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Health care providers' assessments of the quality of advanced-cancer care in Latin American medical institutions: a comparison of predictors in five countries: Argentina, Brazil, Cuba, Mexico, and Peru.
  • This paper describes an innovative Pan-American survey on advanced-cancer care and examines the quality-of-care provided by Latin American institutions.
  • A convenience sample of 777 physicians and nurses who treat cancer patients in Argentina, Brazil, Cuba, Mexico, and Peru were surveyed.
  • Barring respondents from Cuba, providers from the other four nations who practice in public institutions rated the quality of advanced-cancer care in their own institutions lower than those practicing in private hospitals or specialized cancer centers.
  • Other institutional quality-of-care predictors included type of city, affordability-of-care ratings, availability of opioid analgesics, where patients die, barriers to cancer pain management, and the provider's specialty and gender.
  • These findings highlight the need for providing accessible care and services to improve the quality of advanced-cancer care in Latin American institutions.
  • Efforts should be aimed at improving the care offered in public institutions and addressing other types of disparities that may exist within countries by creating supportive and palliative cancer care programs that are accessible and affordable to those most in need.
  • [MeSH-minor] Argentina. Brazil. Cancer Care Facilities. Cuba. Disease Progression. Health Surveys. Hospitals, Private. Hospitals, Public. Humans. Latin America. Mexico. Peru. Practice Patterns, Physicians'

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19042817.001).
  • [ISSN] 1536-0539
  • [Journal-full-title] Journal of pain & palliative care pharmacotherapy
  • [ISO-abbreviation] J Pain Palliat Care Pharmacother
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Hutton JL, Baracos VE, Wismer WV: Chemosensory dysfunction is a primary factor in the evolution of declining nutritional status and quality of life in patients with advanced cancer. J Pain Symptom Manage; 2007 Feb;33(2):156-65
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemosensory dysfunction is a primary factor in the evolution of declining nutritional status and quality of life in patients with advanced cancer.
  • Alterations in taste and smell functions have been reported in cancer patients.
  • Although these senses are known to be particularly affected by chemotherapy, many features of chemosensory perception in cancer patients remain obscure.
  • To assess this relationship, self-perceived taste and smell function were evaluated using a validated questionnaire in 66 patients with advanced cancer receiving palliative care (median survival 7.4 months).
  • Severe chemosensory dysfunction is persistent well beyond the window of active therapy in patients with advanced cancer and represents a primary factor relating to malnutrition, wasting, and poor QOL.
  • Further research is required to identify appropriate strategies to alleviate this important group of symptoms, to determine whether intervention will improve QOL, and to match foods and diet to the unique chemosensory profile of advanced cancer patients.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Taste and Smell Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17280921.001).
  • [ISSN] 0885-3924
  • [Journal-full-title] Journal of pain and symptom management
  • [ISO-abbreviation] J Pain Symptom Manage
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


9. Sherman DW, Ye XY, McSherry C, Calabrese M, Parkas V, Gatto M: Spiritual well-being as a dimension of quality of life for patients with advanced cancer and AIDS and their family caregivers: results of a longitudinal study. Am J Hosp Palliat Care; 2005 Sep-Oct;22(5):349-62
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spiritual well-being as a dimension of quality of life for patients with advanced cancer and AIDS and their family caregivers: results of a longitudinal study.
  • Based on a longitudinal, quality-of-life study, this article presents pilot data regarding the spiritual well-being of patients with advanced cancer or AIDS and their family caregivers.


10. Orrevall Y, Tishelman C, Permert J: Home parenteral nutrition: a qualitative interview study of the experiences of advanced cancer patients and their families. Clin Nutr; 2005 Dec;24(6):961-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Home parenteral nutrition: a qualitative interview study of the experiences of advanced cancer patients and their families.
  • BACKGROUND & AIM: The benefit of home parenteral nutrition (HPN) to advanced cancer patients is often debated and an evidence-base for parenteral nutrition (PN) in palliative care is lacking.
  • The aim of this study is to investigate the experiences of HPN from the perspective of advanced cancer patients and their family members.
  • METHODS: Semi-structured interviews were conducted with 13 advanced cancer patients with experience of HPN and 11 family members.
  • Positive statements about HPN were often coupled to the benefits of being enrolled in advanced home care.
  • CONCLUSION: This study indicates that the interviewed cancer patients and their family members experienced physical, social and psychological benefits from HPN treatment.


11. Kelly L, White S, Stone PC: The B12/CRP index as a simple prognostic indicator in patients with advanced cancer: a confirmatory study. Ann Oncol; 2007 Aug;18(8):1395-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The B12/CRP index as a simple prognostic indicator in patients with advanced cancer: a confirmatory study.
  • BACKGROUND: The vitamin B(12)/C-reactive protein Index (BCI) has been proposed as a prognostic indicator in patients with advanced cancer.
  • PATIENTS AND METHODS: Patients with advanced cancer provided a blood specimen for analysis.
  • CONCLUSIONS: An elevated BCI (>40,000) predicts poor survival in patients with advanced cancer.

  • Hazardous Substances Data Bank. CYANOCOBALAMIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17513884.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 9007-41-4 / C-Reactive Protein; P6YC3EG204 / Vitamin B 12
  •  go-up   go-down


12. Okamoto Y, Tsuneto S, Matsuda Y, Inoue T, Tanimukai H, Tazumi K, Ono Y, Kurokawa N, Uejima E: A retrospective chart review of the antiemetic effectiveness of risperidone in refractory opioid-induced nausea and vomiting in advanced cancer patients. J Pain Symptom Manage; 2007 Aug;34(2):217-22
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A retrospective chart review of the antiemetic effectiveness of risperidone in refractory opioid-induced nausea and vomiting in advanced cancer patients.
  • Nausea and vomiting are distressing symptoms in advanced cancer patients.
  • Among the causes is opioid therapy, the mainstay of cancer pain management.
  • When nausea or other opioid side effects occur, it may hamper pain management and undermine the quality of life of cancer patients.
  • We conducted a retrospective chart review to examine whether risperidone is useful for opioid-induced nausea and vomiting in advanced cancer patients (n=20).
  • This observation suggests that risperidone can be an effective antiemetic drug in the treatment of refractory opioid-induced nausea and vomiting in advanced cancer patients.

  • Genetic Alliance. consumer health - Nausea.
  • Genetic Alliance. consumer health - Vomiting.
  • MedlinePlus Health Information. consumer health - Nausea and Vomiting.
  • Hazardous Substances Data Bank. RISPERIDONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17544249.001).
  • [ISSN] 0885-3924
  • [Journal-full-title] Journal of pain and symptom management
  • [ISO-abbreviation] J Pain Symptom Manage
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 0 / Dopamine Antagonists; L6UH7ZF8HC / Risperidone
  •  go-up   go-down


13. Zhang S, Xu G, Liu C, Xiao S, Sun Y, Su X, Cai Y, Li D, Xu B: Clinical study of recombinant adenovirus-p53 (Adp53) combined with hyperthermia in advanced cancer (a report of 15 cases). Int J Hyperthermia; 2005 Nov;21(7):631-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical study of recombinant adenovirus-p53 (Adp53) combined with hyperthermia in advanced cancer (a report of 15 cases).
  • The study was to evaluate the efficacy of the Adp53 combined with hyperthermia on advanced cancer.
  • Fifteen patients with advanced cancer were enrolled in this clinical trial.
  • In conclusion, Adp53 combined with hyperthermia was safe and effective in patients with advanced cancer and p53 gene therapy was potential to thermosensitize in advanced cancer.
  • [MeSH-minor] Adenoviruses, Human / genetics. Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Genes, p53. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / therapy

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16304714.001).
  • [ISSN] 0265-6736
  • [Journal-full-title] International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  • [ISO-abbreviation] Int J Hyperthermia
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Recombinant Proteins; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


14. Mercadante S, Villari P, Ferrera P, David F, Intravaia G: High-dose furosemide and small-volume hypertonic saline solution infusion for the treatment of leg edema in advanced cancer patients. J Pain Symptom Manage; 2009 Mar;37(3):419-23
Hazardous Substances Data Bank. FUROSEMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose furosemide and small-volume hypertonic saline solution infusion for the treatment of leg edema in advanced cancer patients.
  • Peripheral edema is a common feature in populations with advanced cancer, although it is seldom recognized.
  • The aim of this prospective study was to evaluate the efficacy and tolerability of high-dose furosemide and small-volume hypertonic saline solution infusion in reducing leg edema in patients with advanced cancer treated unsuccessfully with diuretics.
  • To be eligible to enter the trial, advanced cancer patients had to have diffuse bilateral leg edema unresponsive to common doses of diuretics.
  • These observations suggest that high-dose furosemide and small-volume saline may be an effective strategy for the treatment of peripheral edema in patients with advanced cancer.

  • Genetic Alliance. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - Edema.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18790601.001).
  • [ISSN] 1873-6513
  • [Journal-full-title] Journal of pain and symptom management
  • [ISO-abbreviation] J Pain Symptom Manage
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Diuretics; 0 / Saline Solution, Hypertonic; 7LXU5N7ZO5 / Furosemide
  •  go-up   go-down


15. Delgado-Guay MO, Yennurajalingam S, Bruera E: Delirium with severe symptom expression related to hypercalcemia in a patient with advanced cancer: an interdisciplinary approach to treatment. J Pain Symptom Manage; 2008 Oct;36(4):442-9
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Delirium with severe symptom expression related to hypercalcemia in a patient with advanced cancer: an interdisciplinary approach to treatment.
  • Delirium is considered to be multifactorial, especially in elderly patients and those with advanced cancer, and can cause significant distress.
  • Hypercalcemia is one of the reversible metabolic causes of delirium in patients with advanced cancer.

  • MedlinePlus Health Information. consumer health - Delirium.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18440772.001).
  • [ISSN] 1873-6513
  • [Journal-full-title] Journal of pain and symptom management
  • [ISO-abbreviation] J Pain Symptom Manage
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Martinez-Balibrea E, Abad A, Valladares M, Martinez-Villacampa M, Aranda E, Marcuello E, Benavides M, Martinez-Cardús A, Ginés A, Manzano JL, Spanish Group for the Treatment of Digestive Tumors: Pharmacogenetic analysis of TS and UGT1A polymorphisms predictive for response and toxicity in Spanish patients with advanced colorectal cancer treated with first-line irinotecan and 5-fluorouracil. J Clin Oncol; 2009 May 20;27(15_suppl):4066

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacogenetic analysis of TS and UGT1A polymorphisms predictive for response and toxicity in Spanish patients with advanced colorectal cancer treated with first-line irinotecan and 5-fluorouracil.
  • The aim of this work was to determine whether UGT1A1, UGT1A7, and UGT1A9 as well as TS polymorphisms affect toxicities and/or outcomes of Spanish patients with advanced colorectal cancer (mCRC) Methods: A total of 149 patients with mCRC were treated either with weekly irinotecan plus high-dose 5FU (FUIRI) or biweekly irinotecan plus 5FU/Leucovorin (FOLFIRI) as first-line chemotherapy (Aranda E; Ann Oncol.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961607.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Gore EM, Bae K, Wong S, Bonner J, Sun A, Schild S, Gaspar LE, Bogart J, Werner-Wasik M, Choy H: A phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small cell lung cancer: Initial analysis of Radiation Therapy Oncology Group 0214. J Clin Oncol; 2009 May 20;27(15_suppl):7506

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small cell lung cancer: Initial analysis of Radiation Therapy Oncology Group 0214.
  • : 7506 Background: The incidence of central nervous system (CNS) metastases is high in patients with locally advanced non-small cell lung cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963476.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Sherman DW, Norman R, McSherry CB: A comparison of death anxiety and quality of life of patients with advanced cancer or AIDS and their family caregivers. J Assoc Nurses AIDS Care; 2010 Mar-Apr;21(2):99-112
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparison of death anxiety and quality of life of patients with advanced cancer or AIDS and their family caregivers.
  • Based on a sample of 101 patients (63 patients with AIDS and 38 with advanced cancer) and 79 family caregivers (43 AIDS patients' caregivers and 36 cancer patients' caregivers), this study examined the death anxiety of patients with advanced cancer and patients with AIDS and that of their family caregivers and the relationship of death anxiety and quality of life.
  • The results indicated that AIDS patients expressed greater death anxiety than cancer patients, but death anxiety was not different among family caregivers.
  • Both AIDS and cancer patients experienced greater death anxiety than their caregivers.


19. Sasaki T, Isayama H, Nakai Y, Ito Y, Togawa O, Yagioka H, Kogure H, Yasuda I, Hasebe O, Maetani I: Multicenter phase II study of gemcitabine (GEM) plus S-1 in patients (pts) with advanced biliary tract cancer (BTC). J Clin Oncol; 2009 May 20;27(15_suppl):e15516

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicenter phase II study of gemcitabine (GEM) plus S-1 in patients (pts) with advanced biliary tract cancer (BTC).
  • : e15516 Background: Pts with advanced BTC have a poor prognosis and no standard palliative chemotherapy has been defined.
  • The purpose of this prospective multicenter phase II study was to evaluate the efficacy and safety of GEM plus S-1 combination therapy in pts with advanced BTC.
  • METHODS: Pts with advanced BTC, with at least one measurable lesion were eligible for this study.
  • CONCLUSIONS: GEM plus S- 1 combination therapy showed promising efficacy and good tolerability in pts with advanced BTC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962281.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Strasser F, Binswanger J, Cerny T, Kesselring A: Fighting a losing battle: eating-related distress of men with advanced cancer and their female partners. A mixed-methods study. Palliat Med; 2007 Mar;21(2):129-37
MedlinePlus Health Information. consumer health - Stress.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fighting a losing battle: eating-related distress of men with advanced cancer and their female partners. A mixed-methods study.
  • BACKGROUND: Anorexia/cachexia is a frequent complication of advanced cancer with poorly understood psychosocial impact or eating-related distress (ERD) on both patients and family members.
  • To assist palliative care practitioners manage this important psychosocial aspect of care, we aimed to discover and describe elements of ERD, focusing on male patients with advanced cancer and their female partners.
  • CONCLUSION: Anorexia/cachexia of male cancer patients affects the cooking at home, a couple's daily eating routines, and their spousal relationship.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17344261.001).
  • [ISSN] 0269-2163
  • [Journal-full-title] Palliative medicine
  • [ISO-abbreviation] Palliat Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


21. Cherny NI: Evaluation and management of treatment-related diarrhea in patients with advanced cancer: a review. J Pain Symptom Manage; 2008 Oct;36(4):413-23
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation and management of treatment-related diarrhea in patients with advanced cancer: a review.
  • Diarrhea is a common and significant problem among patients with advanced cancer.
  • The causes of diarrhea among patients with advanced cancer are diverse and some causes of diarrhea require specific therapies.
  • Palliative care clinicians, particularly those dealing with patients receiving ongoing disease-modifying therapies, must be familiar with the common causes of diarrhea among cancer patients and the strategies to evaluate and manage these common and distressing symptoms.

  • Genetic Alliance. consumer health - Diarrhea.
  • MedlinePlus Health Information. consumer health - Diarrhea.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18411014.001).
  • [ISSN] 1873-6513
  • [Journal-full-title] Journal of pain and symptom management
  • [ISO-abbreviation] J Pain Symptom Manage
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antidiarrheals
  • [Number-of-references] 80
  •  go-up   go-down


22. Okamura M, Akizuki N, Nakano T, Shimizu K, Ito T, Akechi T, Uchitomi Y: Clinical experience of the use of a pharmacological treatment algorithm for major depressive disorder in patients with advanced cancer. Psychooncology; 2008 Feb;17(2):154-60
Hazardous Substances Data Bank. AMITRIPTYLINE HYDROCHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical experience of the use of a pharmacological treatment algorithm for major depressive disorder in patients with advanced cancer.
  • The objective of this study was to describe the applicability and the dropout of the pharmacological treatment algorithm for major depressive disorder in patients with advanced cancer.
  • Psychiatrists treated major depressive disorder in advanced cancer patients on the basis of the algorithm.
  • [MeSH-minor] Adult. Aged. Alprazolam / therapeutic use. Amitriptyline / therapeutic use. Anxiety Disorders / epidemiology. Anxiety Disorders / prevention & control. Anxiety Disorders / psychology. Central Nervous System Stimulants / therapeutic use. Clomipramine / therapeutic use. Disease Progression. Drug Therapy, Combination. Female. Humans. Male. Methylphenidate / therapeutic use. Middle Aged. Neoplasm Staging. Prognosis. Severity of Illness Index

  • Genetic Alliance. consumer health - Major depressive disorder.
  • MedlinePlus Health Information. consumer health - Antidepressants.
  • Hazardous Substances Data Bank. METHYLPHENIDATE .
  • Hazardous Substances Data Bank. ALPRAZOLAM .
  • Hazardous Substances Data Bank. Clomipramine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17461435.001).
  • [ISSN] 1057-9249
  • [Journal-full-title] Psycho-oncology
  • [ISO-abbreviation] Psychooncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antidepressive Agents; 0 / Central Nervous System Stimulants; 12794-10-4 / Benzodiazepines; 1806D8D52K / Amitriptyline; 207ZZ9QZ49 / Methylphenidate; NUV44L116D / Clomipramine; YU55MQ3IZY / Alprazolam
  •  go-up   go-down


23. Mohri T, Mohri Y, Ward DG, Wei W, Qi Y, Martin A, Kusunoki M, Johnson PJ: Discovery of a tumor-specific biomarker for gastric cancer using proteomic analysis in tissue and serum. J Clin Oncol; 2009 May 20;27(15_suppl):e15582

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discovery of a tumor-specific biomarker for gastric cancer using proteomic analysis in tissue and serum.
  • : e15582 Background: Gastric cancer is curable at an early stage.
  • However, most cases are diagnosed at an advanced stage because of the lack of screening programs.
  • METHODS: We explored surface-enhanced laser desorption/ionization time-of-flight mass spectrometry to elucidate potential protein biomarkers of gastric cancer.
  • Twenty-one resected gastric cancer samples were compared with matched adjacent normal mucosa samples.
  • Serum from patients with gastric cancer (n=51) was compared with patients with benign gastric diseases (n=29).
  • RESULTS: Comparisons of surface-enhanced laser desorption /ionization time-of-flight mass spectrometry spectra of 21 gastric cancer tissue extracts with paired adjacent normal mucosa showed a total of 56 differentially expressed protein peaks (p<0.05; Wilcoxon test).
  • Twenty-two were up-regulated in gastric cancer tissue, whereas 34 were down-regulated.
  • The surface- enhanced laser desorption /ionization time-of-flight mass spectrometry spectra of serum contained 130 peaks, of which 67 were significantly associated with gastric cancer (p<0.05; Wilcoxon test).
  • We found five proteomic features (mass charge values of 2273, 3143, 3372, 3444, 3485) that were significantly up-regulated in both gastric cancer tissue and serum from gastric cancer patients.
  • CONCLUSIONS: Serum biomarker panels associated with tumor tissue are capable of distinguishing gastric cancer patients from non-cancer ones.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962357.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Fetterly GJ, Brady WE, LeVea CM, Litwin AM, Zagst PD, Prey JD, Tarquini M, Giardina MK, Iyer RV, Khushalani NI: A phase I pharmacokinetic (PK) study of vorinostat (V) in combination with irinotecan (I), 5-fluorouracil (5FU), and leucovorin (FOLFIRI) in advanced upper gastrointestinal cancers (AGC). J Clin Oncol; 2009 May 20;27(15_suppl):e15540

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I pharmacokinetic (PK) study of vorinostat (V) in combination with irinotecan (I), 5-fluorouracil (5FU), and leucovorin (FOLFIRI) in advanced upper gastrointestinal cancers (AGC).
  • : e15540 Background: Currently, advanced AGC has no clear standard regimen.
  • The loss of transforming growth factor-β (TGFβ) response contributes to oncogenesis and has been described in gastric cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962309.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Tkaczuk KH, Tait NS, Ioffe O, Tan M, Mohiuddin M, Chumsri S, VanEcho DA, Sutula MJ, Lesko S, Deamond S, Ts'o P: Drug Response Indicator Test (DRIT) as a predictive test for treatment outcomes in advanced breast cancer patients (ABC). J Clin Oncol; 2009 May 20;27(15_suppl):1119

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Drug Response Indicator Test (DRIT) as a predictive test for treatment outcomes in advanced breast cancer patients (ABC).
  • DRIT may allow physicians to choose more effective drug treatments before initiation of therapy and improve the efficacy and toxicity profile of cancer therapies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962198.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Herbst RS, Sun Y, Korfee S, Germonpré P, Saijo N, Zhou C, Wang J, Langmuir P, Kennedy SJ, Johnson BE: Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC). J Clin Oncol; 2009 May 20;27(15_suppl):CRA8003

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962043.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Isla D, Martínez-Trufero J, Morales S, Yubero A, Lambea J, Álvarez I, Polo E, Seguí MA, Pujol E, Pastor P: A pilot study of modified neoadjuvant docetaxel/cisplatin/5-FU (TPF) to concomitant chemoradiotherapy (CT/RT) in locally advanced head and neck cancer (LAHNC): Preliminary results. J Clin Oncol; 2009 May 20;27(15_suppl):6039

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pilot study of modified neoadjuvant docetaxel/cisplatin/5-FU (TPF) to concomitant chemoradiotherapy (CT/RT) in locally advanced head and neck cancer (LAHNC): Preliminary results.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961914.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Biganzoli L, Cortes-Funes H, Thomssen C, Pritchard KI, Pierga J, Kupp A, Borstnar S, Smith I: Tolerability and efficacy of first-line bevacizumab (B) plus chemotherapy (CT) in elderly patients with advanced breast cancer (aBC): Subpopulation analysis of the MO19391 study. J Clin Oncol; 2009 May 20;27(15_suppl):1032

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tolerability and efficacy of first-line bevacizumab (B) plus chemotherapy (CT) in elderly patients with advanced breast cancer (aBC): Subpopulation analysis of the MO19391 study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961081.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Arkenau H, Evans J, Lokelma M, Roxburgh P, Morisson R, Coffey M, Gill G, Mettinger K, Thompson B, de Bono J: A phase I study of the combination of intravenous Reolysin (REO) and gemcitabine (GEM) in patients (pts) with advanced cancer. J Clin Oncol; 2009 May 20;27(15_suppl):3584

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of the combination of intravenous Reolysin (REO) and gemcitabine (GEM) in patients (pts) with advanced cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961749.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. van den Heuvel MM, Belderbos J, Dalesio O, van der Pol M, Uitterhoeve L, van de Vaart P, Verheij M, van Zandwijk N: Cetuximab in combination with concurrent chemoradiotherapy (CRT) in locally advanced non-small cell lung carcinoma (NSCLC): A feasibility study. J Clin Oncol; 2009 May 20;27(15_suppl):7540

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cetuximab in combination with concurrent chemoradiotherapy (CRT) in locally advanced non-small cell lung carcinoma (NSCLC): A feasibility study.
  • : 7540 Background: Despite modest benefits from CRT regimens in patients with locally advanced NSCLC, more efficacious treatment options are needed.
  • METHODS: Patients with non-operable locally advanced NSCLC received cetuximab (400 mg/m<sup>2</sup> on day 1, 250 mg/m<sup>2</sup> q1w from weeks 2-6) in combination with cisplatin (6 mg/m<sup>2</sup> q1d from weeks 2-6), and RT (66 Gy in 24 fractions from weeks 2-6).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963316.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Correa-Velez I, Clavarino A, Eastwood H: Surviving, relieving, repairing, and boosting up: reasons for using complementary/alternative medicine among patients with advanced cancer: a thematic analysis. J Palliat Med; 2005 Oct;8(5):953-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surviving, relieving, repairing, and boosting up: reasons for using complementary/alternative medicine among patients with advanced cancer: a thematic analysis.
  • BACKGROUND: Patients with advanced cancer commonly use complementary and alternative medicine (CAM), however, little research has been undertaken on their reasons for doing so.
  • OBJECTIVES: This study sought to identify in detail the reasons for using CAM among patients with advanced cancer.
  • SETTING/SUBJECTS: Interviews conducted with 39 patients who were participating in a longitudinal study exploring the levels of palliative care received by patients with cancer in Brisbane, Australia.
  • All participants were receiving or had received conventional cancer treatments.
  • RESULTS: Most participants self-treated with CAM and perceived CAM modalities as complementary rather than alternative to conventional cancer treatments.
  • Within this context, this group of people used CAM to prolong their survival, palliate their symptoms or alleviate the side effects of conventional cancer treatments, detoxify their bodies, boost immunity and enhance their overall quality of life.
  • CONCLUSION: When facing an incurable life-threatening illness such as advanced cancer, the decision to use CAM is a pragmatic one.
  • Screening for physical, emotional, and spiritual discomfort associated not only with the disease but with some of the cancer treatments needs to be given a prominent place in the clinical encounter.
  • Patients with cancer want to know more about how to maintain or improve their quality of life during and after surgery, radiation, or chemotherapy.


32. Vaccaro V, Cuppone F, Loupakis F, Milella M, Carlini P, Nisticò C, Falcone A, Terzoli E, Cognetti F, Bria E: Magnitude of benefit of the addition of bevacizumab (BEVA) to first-line chemotherapy (CT) for advanced/metastatic colorectal cancer (MCRC): Meta-analysis of randomized clinical trials. J Clin Oncol; 2009 May 20;27(15_suppl):e15021

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnitude of benefit of the addition of bevacizumab (BEVA) to first-line chemotherapy (CT) for advanced/metastatic colorectal cancer (MCRC): Meta-analysis of randomized clinical trials.
  • The absolute benefit provided into an unselected population for molecular features should be considered of paramount importance for advanced disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964416.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Syrigos KN, Bacoyiannis C, Makatsoris T, Bamias A, Klouvas G, Nicolaides C, Boukovinas I, Linardou E, Fountzilas G, Kosmidis P: Paclitaxel versus oral vinorelbine in patients with advanced non-small cell lung cancer (NSCLC) with performance status (PS) 2: A randomized phase II study. J Clin Oncol; 2009 May 20;27(15_suppl):e19035

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel versus oral vinorelbine in patients with advanced non-small cell lung cancer (NSCLC) with performance status (PS) 2: A randomized phase II study.
  • : e19035 Background: The optimal treatment of patients with advanced NSCLC and PS 2 is not well established.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962124.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Berman DM, Wolchok J, Weber J, Hamid O, O'Day S, Chasalow SD: Association of peripheral blood absolute lymphocyte count (ALC) and clinical activity in patients (pts) with advanced melanoma treated with ipilimumab. J Clin Oncol; 2009 May 20;27(15_suppl):3020

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of peripheral blood absolute lymphocyte count (ALC) and clinical activity in patients (pts) with advanced melanoma treated with ipilimumab.
  • : 3020 Background: Ipilimumab, an anti-CTLA-4 monoclonal antibody, induces durable survival benefits in advanced melanoma pts.
  • Peripheral ALC from routine safety labs were collected from 533 pts with unresectable stage III/IV malignant melanoma treated with ipilimumab 0.3, 3, or 10 mg/kg (recommended dose) in 4 Phase II studies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962073.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Laheru D, Rudek M, Taylor G, Goldsweig H, Rajeshkumar NV, Linden S, Angenendt M, Le D, Donehower R, Jimeno A, Hidalgo M: Integrated development of s-trans, trans-farnesylthiosalicyclic acid (FTS, salirasib) in advanced pancreatic cancer. J Clin Oncol; 2009 May 20;27(15_suppl):4529

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Integrated development of s-trans, trans-farnesylthiosalicyclic acid (FTS, salirasib) in advanced pancreatic cancer.
  • : 4529 Background: The Ras signaling pathway stands as a strategic target in pancreatic cancer.
  • Here we studied the activity of this agent in patients with advanced pancreatic cancer.
  • METHODS: Patients with treatment naïve advanced peri-ampullary cancer were treated with gemcitabine (Gem) administered at standard dose and schedule + FTS administered orally at doses of 200-800 mg bid 21 days of a 28 day cycle.
  • 4. Salirasib mechanism of Ras inhibition is confirmed by reduction of tumor Ras in pancreatic cancer patients.
  • 5. Salirasib warrants evaluation in a controlled study with gemcitabine in pancreatic cancer; doses of 600 or 400 mg b.i.d. are recommended.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962713.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Lewis L, Frank R, Dandamudi UB, Gallagher J, Zhao L, Woo M, Hirawat S, Shapiro GI: Influence of food on the pharmacokinetics (PK) of panobinostat (LBH589), an orally active histone deacetylase inhibitor, in patients with advanced cancer. J Clin Oncol; 2009 May 20;27(15_suppl):2550

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of food on the pharmacokinetics (PK) of panobinostat (LBH589), an orally active histone deacetylase inhibitor, in patients with advanced cancer.
  • : 2550 Background: The effect of food on the bioavailability and PK of panobinostat (PAN) are of considerable importance in allowing appropriate dosing of chronic oral cancer therapy.
  • METHODS: Patients (pts) with advanced cancer received 20 mg PAN twice a week of a 21-day cycle and were randomized to receive 1 of 6 treatment sequences where PAN PK was evaluated weekly under fasting, high fat and normal breakfast.
  • CONCLUSIONS: Since the overall extent of absorption and variability was not changed due to food, PAN administration with or without food is unlikely to significantly impact systemic PAN exposure in cancer patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961876.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Agarwala AK, Hanna N, McCollum A, Bechar N, DiMaio M, Yu M, Tong Y, Becerra CR, Choy H: Preoperative cetuximab and radiation (XRT) for patients (pts) with surgically resectable esophageal and gastroesophageal junction (GEJ) carcinomas: A pilot study from the Hoosier Oncology Group and the University of Texas Southwestern. J Clin Oncol; 2009 May 20;27(15_suppl):4557

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cetuximab, when combined with XRT is effective treatment for locally advanced cancers of the head and neck.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963028.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Stockler MR, O'Connell R, Nowak AK, Goldstein D, Turner J, Wilcken NR, Wyld D, Abdi EA, Glasgow A, Beale PJ, Jefford M, Dhillon H, Heritier S, Carter C, Hickie IB, Simes RJ, Zoloft's Effects on Symptoms and survival Time Trial Group: Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. Lancet Oncol; 2007 Jul;8(7):603-12
Hazardous Substances Data Bank. SERTRALINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial.
  • BACKGROUND: Depression, anxiety, fatigue, and impaired wellbeing are common, important, and closely related in advanced cancer.
  • We aimed to identify the effects of an established antidepressant on these symptoms and survival in patients with advanced cancer who did not have major depression as assessed by clinicians.
  • METHODS: Between July, 2001, and February, 2006, 189 patients with advanced cancer were randomly assigned sertraline 50 mg (n=95), or placebo (n=94), once per day.
  • The primary outcome was depression as assessed by the Centre for Epidemiologic Studies Depression scale (CES-D); the main secondary outcomes were: anxiety as assessed by Hospital Anxiety and Depression Scales (HADS-A); overall quality of life and fatigue as assessed by Functional Assessment of Cancer Therapy General and Fatigue scales (FACT-G and FACT-F, respectively); and clinicians' ratings of quality of life by use of Spizter's Quality of Life Index (SQLI).
  • INTERPRETATION: Sertraline did not improve symptoms, wellbeing, or survival in patients with advanced cancer who do not have major depression, and should be reserved for those with a proven indication.

  • Genetic Alliance. consumer health - Depression.
  • Genetic Alliance. consumer health - Major depressive disorder.
  • MedlinePlus Health Information. consumer health - Antidepressants.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet Oncol. 2007 Jul;8(7):567-8 [17613418.001]
  • [ErratumIn] Lancet Oncol. 2007 Jul 8;8(7):574
  • (PMID = 17548243.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ISRCTN/ ISRCTN72466475
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antidepressive Agents; 0 / Placebos; QUC7NX6WMB / Sertraline
  •  go-up   go-down


39. Sherman DW, Ye XY, Beyer McSherry C, Parkas V, Calabrese M, Gatto M: Symptom assessment of patients with advanced cancer and AIDS and their family caregivers: the results of a quality-of-life pilot study. Am J Hosp Palliat Care; 2007 Oct-Nov;24(5):350-65
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Symptom assessment of patients with advanced cancer and AIDS and their family caregivers: the results of a quality-of-life pilot study.
  • This longitudinal pilot study examined differences in demographic characteristics of 101 patients with advanced illness (cancer, AIDS) and 81 Family caregivers, evaluated the reliability of the Memorial Symptom Assessment Scale for these patients and their family caregivers; obtained preliminary data regarding similarities or differences in the symptom experience oF these patients and their family caregivers and changes in symptoms over time; and identified demographic variables that may be potential covariates related to the symptom experience.
  • All demographic variables were significantly different for patients with advanced cancer and AIDS, and their symptom experience is similar only with regard to psychologic symptoms; however, based on the Memorial Symptom Assessment Scale, cancer and AIDS patients and their family caregivers have similar symptom experiences, indicating the need for palliative care for both patients and family.


40. Strasser F, Müller-Käser I, Dietrich D: Evaluating cognitive, emotional, and physical fatigue domains in daily practice by single-item questions in patients with advanced cancer: a cross-sectional pragmatic study. J Pain Symptom Manage; 2009 Oct;38(4):505-14
MedlinePlus Health Information. consumer health - Fatigue.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluating cognitive, emotional, and physical fatigue domains in daily practice by single-item questions in patients with advanced cancer: a cross-sectional pragmatic study.
  • To assess cancer-related fatigue (CRF), multidimensional questionnaires are required.
  • Sixty-one fatigued patients with advanced cancer completed SIF assessments (visual analog scales for global fatigue and for fatigue in the cognitive, emotional, and physical domains, respectively), and the Brief Fatigue Inventory (BFI), the Fatigue Assessment Questionnaire (FAQ), the Hospital Anxiety and Depression Scale (HADS), and the European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life-C30 (QLQ-C30).
  • These data suggest that three simple SIF questions permit rapid assessment of the physical and cognitive and probably the emotional domains of CRF in patients with advanced cancer.

  • MedlinePlus Health Information. consumer health - Anxiety.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19822275.001).
  • [ISSN] 1873-6513
  • [Journal-full-title] Journal of pain and symptom management
  • [ISO-abbreviation] J Pain Symptom Manage
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Maltoni M, Caraceni A, Brunelli C, Broeckaert B, Christakis N, Eychmueller S, Glare P, Nabal M, Viganò A, Larkin P, De Conno F, Hanks G, Kaasa S, Steering Committee of the European Association for Palliative Care: Prognostic factors in advanced cancer patients: evidence-based clinical recommendations--a study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol; 2005 Sep 1;23(25):6240-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in advanced cancer patients: evidence-based clinical recommendations--a study by the Steering Committee of the European Association for Palliative Care.
  • PURPOSE: To offer evidence-based clinical recommendations concerning prognosis in advanced cancer patients.
  • Only studies on patients with advanced cancer and survival < or = 90 days were included.
  • Recommendations on the use of other prognostic factors, such as performance status, symptoms associated with cancer anorexia-cachexia syndrome (weight loss, anorexia, dysphagia, and xerostomia), dyspnea, delirium, and some biologic factors (leukocytosis, lymphocytopenia, and C-reactive protein), reached level B.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16135490.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  • [Number-of-references] 80
  •  go-up   go-down


42. Lee MS, Yang SH, Lee KK, Moon SR: Effects of Qi therapy (external Qigong) on symptoms of advanced cancer: a single case study. Eur J Cancer Care (Engl); 2005 Dec;14(5):457-62
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of Qi therapy (external Qigong) on symptoms of advanced cancer: a single case study.
  • The aim of this study was to examine the effectiveness of Qi therapy (external Qigong) in the management of symptoms of advanced cancer in a man.
  • We used a single case study design to evaluate the effectiveness of Qi therapy (external Qigong) in a 35-year-old man with advanced cancer (Stage IV) involving metastases in the stomach, lung and bone (Karnofsky performance scale: KPS, 40: requires special care and assistance, disabled).
  • A visual analogue scale (VAS) was used to assess the patient's self-reported symptoms of cancer over the intervention and follow-up periods.

  • MedlinePlus Health Information. consumer health - Fatigue.
  • MedlinePlus Health Information. consumer health - Insomnia.
  • MedlinePlus Health Information. consumer health - Nausea and Vomiting.
  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16274468.001).
  • [ISSN] 0961-5423
  • [Journal-full-title] European journal of cancer care
  • [ISO-abbreviation] Eur J Cancer Care (Engl)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


43. Koutcher L, Fury M, Wolden S, Zhang Z, Mo Q, Zelefsky M, Kraus D, Sherman E, Pfister D, Lee N: Comparison of cisplatin (CDDP) and radiation (RT) to cetuximab (C) and RT for locally advanced head and neck cancer (LAHNC): A preliminary analysis. J Clin Oncol; 2009 May 20;27(15_suppl):6042

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of cisplatin (CDDP) and radiation (RT) to cetuximab (C) and RT for locally advanced head and neck cancer (LAHNC): A preliminary analysis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961906.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Drevs J, Medinger M, Mross K, Fuxius S, Hennig J, Buechert M, Thomas A, Unger C, Chen BL, Lebwohl D, Laurent D: A phase IA, open-label, dose-escalating study of PTK787/ZK 222584 administered orally on a continuous dosing schedule in patients with advanced cancer. Anticancer Res; 2010 Jun;30(6):2335-9
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase IA, open-label, dose-escalating study of PTK787/ZK 222584 administered orally on a continuous dosing schedule in patients with advanced cancer.
  • Seventy-one patients with advanced cancer were enrolled to receive once daily dosing.
  • CONCLUSION: An MTD was not reached in this study but, based on these data and findings from other studies, 1200 mg was found to be the optimum dose of PTK/ZK for patients with advanced cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20651389.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Phthalazines; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 0 / Vascular Endothelial Growth Factor A; 103107-01-3 / Fibroblast Growth Factor 2; 5DX9U76296 / vatalanib
  •  go-up   go-down


45. Yennurajalingam S, Dev R, Walker PW, Reddy SK, Bruera E: Challenges associated with spinal opioid therapy for pain in patients with advanced cancer: a report of three cases. J Pain Symptom Manage; 2010 May;39(5):930-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Challenges associated with spinal opioid therapy for pain in patients with advanced cancer: a report of three cases.
  • Intraspinal opioid therapy has been increasingly used for the management of cancer pain refractory to traditional treatment.
  • However, this approach may present challenges in patients with advanced cancer.
  • Three cases are presented that highlight the challenges associated with using neuraxial analgesia to manage cancer pain that was felt to be "refractory" to conventional treatment.

  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20471553.001).
  • [ISSN] 1873-6513
  • [Journal-full-title] Journal of pain and symptom management
  • [ISO-abbreviation] J Pain Symptom Manage
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics, Opioid
  •  go-up   go-down


46. Ishikawa H, Saeki T, Otani T, Suzuki T, Shimozuma K, Nishino H, Fukuda S, Morimoto K: Aged garlic extract prevents a decline of NK cell number and activity in patients with advanced cancer. J Nutr; 2006 Mar;136(3 Suppl):816S-820S
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aged garlic extract prevents a decline of NK cell number and activity in patients with advanced cancer.
  • Advanced-cancer patients decline in immune functions and quality of life (QOL).
  • The study's subjects were patients with inoperable colorectal, liver, or pancreatic cancer.
  • The primary endpoint was a QOL questionnaire based on the Functional Assessment of Cancer Therapy (FACT).
  • They consisted of 42 patients with liver cancer (84%), 7 patients with pancreatic cancer (14%), and 1 patient with colon cancer (2%).
  • The study showed that administering AGE to patients with advanced cancer of the digestive system improved NK cell activity, but caused no improvement in QOL.

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16484572.001).
  • [ISSN] 0022-3166
  • [Journal-full-title] The Journal of nutrition
  • [ISO-abbreviation] J. Nutr.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Placebos; 0 / Plant Extracts
  •  go-up   go-down


47. Porzio G, Aielli F, Verna L, Aloisi P, Galletti B, Ficorella C: Gabapentin in the treatment of hiccups in patients with advanced cancer: a 5-year experience. Clin Neuropharmacol; 2010 Jul;33(4):179-80
Hazardous Substances Data Bank. GABAPENTIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gabapentin in the treatment of hiccups in patients with advanced cancer: a 5-year experience.
  • AIM: To evaluate safety and efficacy of gabapentin in the treatment of severe chronic hiccups in patients with advanced cancer.
  • CONCLUSION: The results of the study allow suggesting gabapentin at least as a promising drug in the treatment of severe chronic hiccups in advanced cancer patients.

  • MedlinePlus Health Information. consumer health - Hiccups.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20414106.001).
  • [ISSN] 1537-162X
  • [Journal-full-title] Clinical neuropharmacology
  • [ISO-abbreviation] Clin Neuropharmacol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amines; 0 / Calcium Channel Blockers; 0 / Cyclohexanecarboxylic Acids; 56-12-2 / gamma-Aminobutyric Acid; 6CW7F3G59X / gabapentin
  •  go-up   go-down


48. Wu JC, Hakama M, Anttila A, Yen AM, Malila N, Sarkeala T, Auvinen A, Chiu SY, Chen HH: Estimation of natural history parameters of breast cancer based on non-randomized organized screening data: subsidiary analysis of effects of inter-screening interval, sensitivity, and attendance rate on reduction of advanced cancer. Breast Cancer Res Treat; 2010 Jul;122(2):553-66
MedlinePlus Health Information. consumer health - Mammography.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estimation of natural history parameters of breast cancer based on non-randomized organized screening data: subsidiary analysis of effects of inter-screening interval, sensitivity, and attendance rate on reduction of advanced cancer.
  • Estimating the natural history parameters of breast cancer not only elucidates the disease progression but also make contributions to assessing the impact of inter-screening interval, sensitivity, and attendance rate on reducing advanced breast cancer.
  • Computer simulation was implemented to examine the effect of inter-screening interval, sensitivity, and attendance rate on reducing advanced breast cancers.
  • In three-state model, the MST was 2.02 years, and the sensitivity for detecting preclinical breast cancer was 84.83%.
  • Annual, biennial, and triennial screening programs can reduce 53, 37, and 28% of advanced cancer.
  • We demonstrated how to estimate the natural history parameters using a service screening program and applied these parameters to assess the impact of inter-screening interval, sensitivity, and attendance rate on reducing advanced cancer.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20054645.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


49. Chvetzoff G, Perol D, Devaux Y, Lancry L, Rebattu P, Magnet M, Dubost E, Bertrand M, Garcon C, Thevenet G, Gobet S, Arbiol E, Saltel P: [Prospective study on the quality of care and quality of life in advanced cancer patients treated at home or in hospital: intermediate analysis of the Trapado study]. Bull Cancer; 2006 Feb;93(2):213-21
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prospective study on the quality of care and quality of life in advanced cancer patients treated at home or in hospital: intermediate analysis of the Trapado study].
  • The preferences of advanced cancer patients and the impact of cancer management on relatives remain partly unknown.
  • We present the preliminary results of a prospective study evaluating quality of care (QC), quality of life (QoL) and family impact (FI) in advanced cancer patients treated at home or in hospital, depending on their own choice.

  • MedlinePlus Health Information. consumer health - Home Care Services.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16517418.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


50. O'Hara RE, Hull JG, Lyons KD, Bakitas M, Hegel MT, Li Z, Ahles TA: Impact on caregiver burden of a patient-focused palliative care intervention for patients with advanced cancer. Palliat Support Care; 2010 Dec;8(4):395-404
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact on caregiver burden of a patient-focused palliative care intervention for patients with advanced cancer.
  • OBJECTIVE: Caregivers of patients with advanced cancer experience physical and emotional strain that can raise their own risk for morbidity and mortality.
  • METHOD: Caregivers of patients with advanced cancer from the parent study completed a caregiver burden scale and patients completed quality of life, symptom intensity, and depressed mood measures.

  • MedlinePlus Health Information. consumer health - Cancer--Living with Cancer.
  • MedlinePlus Health Information. consumer health - Caregivers.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • MedlinePlus Health Information. consumer health - Stress.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 1999 Dec 15;282(23):2215-9 [10605972.001]
  • [Cites] JAMA. 2009 Aug 19;302(7):741-9 [19690306.001]
  • [Cites] Psychol Aging. 2000 Jun;15(2):259-71 [10879581.001]
  • [Cites] Am J Nurs. 2000 Dec;100(12):26-31; quiz 32 [11202781.001]
  • [Cites] Oncol Nurs Forum. 2001 Aug;28(7):1149-57 [11517848.001]
  • [Cites] J Pain Symptom Manage. 2001 Sep;22(3):752-8 [11532588.001]
  • [Cites] Health Psychol. 2001 Nov;20(6):452-7 [11714188.001]
  • [Cites] Gerontologist. 2002 Jun;42(3):356-72 [12040138.001]
  • [Cites] Soc Sci Med. 2003 Jan;56(1):95-109 [12435554.001]
  • [Cites] Palliat Med. 2003 Jan;17(1):63-74 [12597468.001]
  • [Cites] J Gerontol B Psychol Sci Soc Sci. 2003 Mar;58(2):P112-28 [12646594.001]
  • [Cites] Psychol Aging. 2003 Jun;18(2):250-67 [12825775.001]
  • [Cites] Support Care Cancer. 2003 Oct;11(10):638-43 [12905058.001]
  • [Cites] Palliat Med. 2004 Mar;18(2):108-20 [15046407.001]
  • [Cites] J Palliat Care. 1991 Summer;7(2):6-9 [1714502.001]
  • [Cites] Soc Sci Med. 1995 Feb;40(4):517-28 [7725125.001]
  • [Cites] Cancer Treat Rev. 1996 Jan;22 Suppl A:3-12 [8625346.001]
  • [Cites] J Pain Symptom Manage. 1997 Mar;13(3):138-47 [9114632.001]
  • [Cites] Nurs Res. 1998 Jan-Feb;47(1):2-10 [9478178.001]
  • [Cites] Psychooncology. 1998 Jan-Feb;7(1):3-13 [9516646.001]
  • [Cites] Image J Nurs Sch. 1999;31(2):115-20 [10380385.001]
  • [Cites] Oncol Nurs Forum. 2004 Nov;31(6):1105-17 [15547633.001]
  • [Cites] J Pain Symptom Manage. 2005 Aug;30(2):112-22 [16125026.001]
  • [Cites] J Pain Symptom Manage. 2005 Oct;30(4):329-41 [16256897.001]
  • [Cites] Cancer. 2006 Jan 1;106(1):214-22 [16329131.001]
  • [Cites] N Engl J Med. 2006 Feb 16;354(7):719-30 [16481639.001]
  • [Cites] Am J Hosp Palliat Care. 2006 Jun-Jul;23(3):185-91 [17060277.001]
  • [Cites] Arch Intern Med. 2007 Jan 8;167(1):40-6 [17210876.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4829-34 [17947732.001]
  • [Cites] J Pain Symptom Manage. 2007 Nov;34(5):539-46 [17616333.001]
  • [Cites] J Psychosom Res. 2007 Dec;63(6):617-23 [18061752.001]
  • [Cites] Ann Intern Med. 2008 Jan 15;148(2):147-59 [18195339.001]
  • [Cites] Psychol Bull. 2008 Jan;134(1):1-30 [18193993.001]
  • [Cites] Clin J Oncol Nurs. 2008 Jun;12(3):507-16 [18515250.001]
  • [Cites] Am J Public Health. 2008 Nov;98(11):2092-8 [18511733.001]
  • [Cites] J Clin Oncol. 2008 Dec 20;26(36):5890-5 [19029423.001]
  • [Cites] J Pain Symptom Manage. 2009 Jan;37(1):23-32 [18504093.001]
  • [Cites] Palliat Support Care. 2009 Mar;7(1):75-86 [19619377.001]
  • [Cites] Cancer Treat Res. 1999;100:203-16 [10645504.001]
  • (PMID = 20875202.001).
  • [ISSN] 1478-9523
  • [Journal-full-title] Palliative & supportive care
  • [ISO-abbreviation] Palliat Support Care
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA101704; United States / NCI NIH HHS / CA / CA101704-03; United States / NCI NIH HHS / CA / CA101704-02; United States / NCI NIH HHS / CA / P30 CA023108; United States / NCI NIH HHS / CA / R01 CA101704-01; United States / NCI NIH HHS / CA / R01 CA101704-02; United States / NCI NIH HHS / CA / R01 CA101704-03; United States / NCI NIH HHS / CA / CA101704-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS277192; NLM/ PMC3063059
  •  go-up   go-down


51. Homma A, Oridate N, Suzuki F, Taki S, Asano T, Yoshida D, Onimaru R, Nishioka T, Shirato H, Fukuda S: Superselective high-dose cisplatin infusion with concomitant radiotherapy in patients with advanced cancer of the nasal cavity and paranasal sinuses: a single institution experience. Cancer; 2009 Oct 15;115(20):4705-14
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Superselective high-dose cisplatin infusion with concomitant radiotherapy in patients with advanced cancer of the nasal cavity and paranasal sinuses: a single institution experience.
  • BACKGROUND: The current study aimed to evaluate the efficacy of superselective high-dose cisplatin infusion with concomitant radiotherapy (RADPLAT) for previously untreated patients with advanced cancer of the nasal cavity and paranasal sinuses.
  • CONCLUSIONS: Although a single institution experience, the results of the current study suggest that RADPLAT can cure the majority of patients with advanced cancer of the nasal cavity and paranasal sinuses, as well as preserve organs.
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy / adverse effects. Disease Progression. Female. Humans. Infusions, Intra-Arterial. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Survival Analysis. Thiosulfates / administration & dosage

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 American Cancer Society.
  • (PMID = 19634162.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Thiosulfates; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


52. Nole F, Munzone E, Bertolini F, Sandri MT, Petralia G, Adamoli L, Radice D, Cullura D, di Pietro A, Goldhirsch A: Circulating endothelial cells (CECs), progenitors (CEPs), and circulating tumor cells (CTCs) for prediction of response in patients with advanced breast cancer (ABC) receiving metronomic oral vinorelbine (oV): Preliminary results. J Clin Oncol; 2009 May 20;27(15_suppl):e14572

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating endothelial cells (CECs), progenitors (CEPs), and circulating tumor cells (CTCs) for prediction of response in patients with advanced breast cancer (ABC) receiving metronomic oral vinorelbine (oV): Preliminary results.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963681.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Brown ER, Charles KA, Hoare SA, Rye RL, Jodrell DI, Aird RE, Vora R, Prabhakar U, Nakada M, Corringham RE, DeWitte M, Sturgeon C, Propper D, Balkwill FR, Smyth JF: A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer. Ann Oncol; 2008 Jul;19(7):1340-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer.
  • Infliximab, an anti-TNF-alpha monoclonal antibody was investigated in this trial of patients with advanced cancer.
  • The primary objectives were to determine the safety profile and biological response of infliximab in a cancer population.
  • Post-treatment samples were measured for changes in plasma and serum TNF-alpha, CCL2, IL-6 and C-reactive protein (CRP).
  • At both doses of infliximab, neutralisation of serum TNF-alpha was observed after 1 h while plasma CCL2, IL-6 and serum CRP were decreased 24 and 48 h following infliximab administration.
  • CONCLUSIONS: Infliximab treatment was safe and well tolerated in patients with advanced cancer.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Infliximab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18325912.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0501974
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / CCL2 protein, human; 0 / Chemokine CCL2; 0 / Interleukin-6; 0 / Tumor Necrosis Factor-alpha; 9007-41-4 / C-Reactive Protein; B72HH48FLU / Infliximab
  •  go-up   go-down


54. Ma CX, Lin L, Gao F, Giuntoli T, Chia YH, Guo Z, McDowell R, Naughton M, Watson M, Ellis M: PIK3CA mutation analysis in recurrent breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):11041

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PIK3CA mutation analysis in recurrent breast cancer.
  • : 11041 Background: Mutations in PIK3CA (encoding p110α catalytic subunit of phosphatidylinositol-3-kinase) are among the most common genetic events identified in breast cancer but the role of these mutations in determining the clinical course of the disease is uncertain.
  • Furthermore the frequency of PIK3CA mutation in metastatic breast cancer samples has not been adequately studied but is an important concern in the design of studies with novel agents designed to inhibit mutant PIK3CA.
  • METHODS: We have established a tumor banking protocol for patients (pts) with metastatic breast cancer.
  • CONCLUSIONS: About one quarter of pts with recurrent/advanced breast cancer carry PIK3CA mutations in samples of recurrent disease, which correlated with positive ER/PR status and a more indolent clinical course.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963981.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Saif MW, Li J, Lamb L, Rosenberg A, Elligers K, Ruta S, Mezes M, Grant N, Liu SH, Chu E, Cheng Y: A phase II study of capecitabine (CAP) plus PHY906 in patients (pts) with advanced pancreatic cancer (APC). J Clin Oncol; 2009 May 20;27(15_suppl):e15508

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of capecitabine (CAP) plus PHY906 in patients (pts) with advanced pancreatic cancer (APC).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962238.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Koolen S, Witteveen PO, Garcia-Ribas I, Callies S, Andre V, Kronemeijer RH, Nol A, Beijnen JH, Voest EE, Schellens JH: Phase I study of oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients (pts) with advanced solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):2576

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients (pts) with advanced solid tumors.
  • One pt with refractory prostate cancer presented a PSA CR as assessed by investigator.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961892.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Heinzerling JH, Hughes RS, Govindan R, Bradley JD, Schiller J, Peng G, Treat J, Obasaju C, Tran T, Choy H: A phase I study of pemetrexed plus carboplatin or cisplatin with concurrent chest radiation therapy (CRT) for patients with locally advanced non-small cell lung cancer (LANSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):7545

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of pemetrexed plus carboplatin or cisplatin with concurrent chest radiation therapy (CRT) for patients with locally advanced non-small cell lung cancer (LANSCLC).
  • Pemetrexed is an effective new chemotherapeutic agent in advanced non-small cell lung cancer.
  • Pemetrexed has also shown preclinical activity as a radiosensitizer in lung cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963321.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Nilsson B, Hendlisz A, Castella M, Aamdal S, Dueland S, Nyakas M, Evans J, Venugopal B, Rasch W, Awada A: First-in-human study of a novel nucleoside analogue, CP-4126, in patients with advanced solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):2577

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First-in-human study of a novel nucleoside analogue, CP-4126, in patients with advanced solid tumors.
  • Stabilisation of disease (≥ 3 months) reported in 5 pts (pancreas, colon and ovarian cancer) lasting between 3.5 to 8 months.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961893.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Wirk B, Perez E: Role of Gemcitabine in Breast Cancer Management: An Update. Semin Oncol; 2006 Feb;33 Suppl 2:6-14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of Gemcitabine in Breast Cancer Management: An Update.
  • Anthracyclines and the taxanes are now used earlier in the course of therapy for metastatic breast cancer, and increasingly as part of adjuvant treatment.
  • The gemcitabine/paclitaxel combination has emerged as part of a new standard of combination therapy for advanced breast cancer, based on phase III data showing superiority of this combination over paclitaxel alone in the first-line therapy setting.
  • Gemcitabine alone, or in combination with paclitaxel and other agents, is also undergoing evaluation in other settings including the refractory metastatic setting, as part of management of patients with HER2-positive disease, and also as part of adjuvant therapy for breast cancer.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28140046.001).
  • [ISSN] 1532-8708
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Malka D, Trarbach T, Fartoux L, Mendiboure J, de la Fouchardière C, Viret F, Assenat E, Boucher E, Rosmorduc O, Greten T: A multicenter, randomized phase II trial of gemcitabine and oxaliplatin (GEMOX) alone or in combination with biweekly cetuximab in the first-line treatment of advanced biliary cancer: Interim analysis of the BINGO trial. J Clin Oncol; 2009 May 20;27(15_suppl):4520

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multicenter, randomized phase II trial of gemcitabine and oxaliplatin (GEMOX) alone or in combination with biweekly cetuximab in the first-line treatment of advanced biliary cancer: Interim analysis of the BINGO trial.
  • : 4520 Background: There is no standard regimen for palliative chemotherapy of advanced biliary cancers.
  • EGFR over-expression has been observed in advanced biliary cancers suggesting that the combination with anti-EGFR monoclonal antibodies may be appropriate.
  • METHODS: Patients with advanced biliary cancer, WHO performance status 0-1, and without prior palliative chemotherapy were eligible for this international, open-label, two-stage, randomized phase II trial.
  • CONCLUSIONS: The GEMOX-cetuximab regimen seems well tolerated in patients with advanced biliary cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962727.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Miller JJ, Frost MH, Rummans TA, Huschka M, Atherton P, Brown P, Gamble G, Richardson J, Hanson J, Sloan JA, Clark MM: Role of a medical social worker in improving quality of life for patients with advanced cancer with a structured multidisciplinary intervention. J Psychosoc Oncol; 2007;25(4):105-19
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of a medical social worker in improving quality of life for patients with advanced cancer with a structured multidisciplinary intervention.
  • <i> BACKGROUND: </i> Patients with advanced cancer face multiple challenges to their quality of life (QOL).
  • The goal of this study was to investigate the impact of participation in a multidisciplinary intervention, including a social service component, on improving the QOL of patients with advanced cancer undergoing radiation therapy.
  • <i> DESIGN: </i> A total of 115 participants with newly diagnosed advanced stage cancer, who were receiving radiation therapy, were randomly assigned to either participate in an 8-session structured multidisciplinary intervention or to receive standard care.
  • <i> CONCLUSIONS: </i> A social work component within a structured multidisciplinary intervention results in significant advantages in the social domain of QOL, and contributes to clinically meaningful improvements in the overall QOL for patients with advanced cancer undergoing active medical treatment.
  • Numerous studies have documented the financial burdens and social changes that may occur with the diagnosis of cancer.
  • [MeSH-major] Health Services / standards. Interdisciplinary Communication. Neoplasm Staging. Neoplasms. Patient Care Team. Quality of Life / psychology. Social Work

  • MedlinePlus Health Information. consumer health - Cancer--Living with Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18032268.001).
  • [ISSN] 0734-7332
  • [Journal-full-title] Journal of psychosocial oncology
  • [ISO-abbreviation] J Psychosoc Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


62. Currow DC, Plummer JL, Cooney NJ, Gorman D, Glare PA: A randomized, double-blind, multi-site, crossover, placebo-controlled equivalence study of morning versus evening once-daily sustained-release morphine sulfate in people with pain from advanced cancer. J Pain Symptom Manage; 2007 Jul;34(1):17-23
Hazardous Substances Data Bank. MORPHINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized, double-blind, multi-site, crossover, placebo-controlled equivalence study of morning versus evening once-daily sustained-release morphine sulfate in people with pain from advanced cancer.
  • The study recruited 45 people with opioid-responsive pain on stable doses of analgesics and advanced cancer from five regional palliative care programs in Australia.
  • This study suggests that any difference between morning and evening dosing of once-daily sustained-release morphine in people with significant opioid-responsive pain and advanced cancer is small and unlikely to be clinically significant for most people.

  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17601560.001).
  • [ISSN] 0885-3924
  • [Journal-full-title] Journal of pain and symptom management
  • [ISO-abbreviation] J Pain Symptom Manage
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 0 / Delayed-Action Preparations; 0 / Placebos; 76I7G6D29C / Morphine
  •  go-up   go-down


63. Yennurajalingam S, Palmer JL, Zhang T, Poulter V, Bruera E: Association between fatigue and other cancer-related symptoms in patients with advanced cancer. Support Care Cancer; 2008 Oct;16(10):1125-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between fatigue and other cancer-related symptoms in patients with advanced cancer.
  • GOALS OF WORK: Although fatigue is the chronic symptom most commonly experienced by patients with advanced cancer, little research has been done on the associations and correlates of fatigue in this population.
  • The aim of this study was, therefore, to determine whether fatigue scores, as measured by the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), are associated with age, gender, type of cancer diagnosed, pain, and other cancer-related symptoms measured using the Edmonton Symptom Assessment Scale (ESAS).
  • MATERIALS AND METHODS: We retrospectively reviewed the FACIT-F (when a higher score denotes lower fatigue) and ESAS (when a lower fatigue score denotes lower fatigue intensity) scores of 268 patients with advanced cancer who had been previously enrolled in clinical trials of therapies for fatigue.
  • RESULTS: We found no univariate association between fatigue score and gender, ethnicity (p = 0.31), or type of cancer diagnosed.

  • MedlinePlus Health Information. consumer health - Fatigue.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2007 Aug 10;25(23):3475-81 [17687152.001]
  • [Cites] Palliat Med. 2008 Jan;22(1):13-32 [18216074.001]
  • [Cites] Crit Rev Oncol Hematol. 2003 Sep;47(3):273-9 [12962901.001]
  • [Cites] Support Care Cancer. 1996 Mar;4(2):82-96 [8673356.001]
  • [Cites] J Clin Oncol. 2001 Jul 15;19(14):3385-91 [11454886.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):2073-8 [16648508.001]
  • [Cites] J Pain Symptom Manage. 2003 Jul;26(1):604-14 [12850643.001]
  • [Cites] Support Care Cancer. 2008 Aug;16(8):943-6 [18071764.001]
  • [Cites] Oncologist. 2000;5(5):353-60 [11040270.001]
  • [Cites] JAMA. 2007 Jan 17;297(3):295-304 [17227981.001]
  • [Cites] J Palliat Med. 2005 Dec;8(6):1144-9 [16351527.001]
  • [Cites] Eur J Cancer. 2007 Apr;43(6):1030-6 [17336052.001]
  • [Cites] J Clin Oncol. 1993 Mar;11(3):570-9 [8445433.001]
  • [Cites] J Palliat Care. 1991 Summer;7(2):6-9 [1714502.001]
  • [Cites] Sch Inq Nurs Pract. 2000 Winter;14(4):275-90; discussion 291-8 [11372188.001]
  • [Cites] J Psychiatr Res. 1975 Nov;12(3):189-98 [1202204.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4439-43 [14645434.001]
  • [Cites] Cancer. 2002 Jan 15;94(2):528-38 [11900238.001]
  • [Cites] J Pain Symptom Manage. 1992 May;7(4):192-5 [1517640.001]
  • [Cites] Cancer. 2000 May 1;88(9):2164-71 [10813730.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(4):743-53 [10673515.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):377-82 [15558809.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1319-28 [11870175.001]
  • [Cites] Ann Oncol. 2000 May;11(5):561-7 [10907949.001]
  • [Cites] J Pain Symptom Manage. 2001 Jun;21(6):456-66 [11397603.001]
  • [Cites] Semin Hematol. 1997 Jul;34(3 Suppl 2):4-12 [9253778.001]
  • [Cites] J Pain Symptom Manage. 2006 Mar;31(3):229-41 [16563317.001]
  • (PMID = 18504622.001).
  • [ISSN] 0941-4355
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01CA1222292.01; United States / NCI NIH HHS / CA / R01CA124481-01; United States / NINR NIH HHS / NR / R01NR010162-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


64. Bakitas M, Lyons KD, Hegel MT, Balan S, Brokaw FC, Seville J, Hull JG, Li Z, Tosteson TD, Byock IR, Ahles TA: Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the Project ENABLE II randomized controlled trial. JAMA; 2009 Aug 19;302(7):741-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the Project ENABLE II randomized controlled trial.
  • CONTEXT: There are few randomized controlled trials on the effectiveness of palliative care interventions to improve the care of patients with advanced cancer.
  • OBJECTIVE: To determine the effect of a nursing-led intervention on quality of life, symptom intensity, mood, and resource use in patients with advanced cancer.
  • DESIGN, SETTING, AND PARTICIPANTS: Randomized controlled trial conducted from November 2003 through May 2008 of 322 patients with advanced cancer in a rural, National Cancer Institute-designated comprehensive cancer center in New Hampshire and affiliated outreach clinics and a VA medical center in Vermont.
  • INTERVENTIONS: A multicomponent, psychoeducational intervention (Project ENABLE [Educate, Nurture, Advise, Before Life Ends]) conducted by advanced practice nurses consisting of 4 weekly educational sessions and monthly follow-up sessions until death or study completion (n = 161) vs usual care (n = 161).
  • RESULTS: A total of 322 participants with cancer of the gastrointestinal tract (41%; 67 in the usual care group vs 66 in the intervention group), lung (36%; 58 vs 59), genitourinary tract (12%; 20 vs 19), and breast (10%; 16 vs 17) were randomized.

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 2008 Oct 8;300(14):1665-73 [18840840.001]
  • [Cites] Arch Intern Med. 2008 Sep 8;168(16):1783-90 [18779466.001]
  • [Cites] J Clin Oncol. 2009 Jan 10;27(2):206-13 [19064979.001]
  • [Cites] Palliat Support Care. 2009 Mar;7(1):75-86 [19619377.001]
  • [Cites] J Pain Symptom Manage. 2009 Jan;37(1):23-32 [18504093.001]
  • [Cites] J Clin Oncol. 2008 Aug 10;26(23):3860-6 [18688053.001]
  • [Cites] Ann Intern Med. 2000 May 16;132(10):825-32 [10819707.001]
  • [Cites] JAMA. 2000 Nov 15;284(19):2476-82 [11074777.001]
  • [Cites] Pharmacoeconomics. 2000 Nov;18(5):419-23 [11151395.001]
  • [Cites] J Pain Symptom Manage. 2001 Jul;22(1):584-90 [11516600.001]
  • [Cites] J Pain Symptom Manage. 2001 Sep;22(3):727-37 [11532586.001]
  • [Cites] Health Aff (Millwood). 2001 Nov-Dec;20(6):64-78 [11816692.001]
  • [Cites] Cancer Control. 2001 Nov-Dec;8(6 Suppl 2):88-93 [11760564.001]
  • [Cites] Qual Life Res. 2002 May;11(3):207-21 [12074259.001]
  • [Cites] JAMA. 2003 Jun 18;289(23):3106-16 [12813116.001]
  • [Cites] J Palliat Med. 2003 Oct;6(5):699-705 [14622449.001]
  • [Cites] Arch Intern Med. 2004 Jan 12;164(1):83-91 [14718327.001]
  • [Cites] J Palliat Med. 2004 Feb;7(1):119-34 [15000796.001]
  • [Cites] BMJ. 2004 Mar 13;328(7440):607 [15016692.001]
  • [Cites] Oncol Nurs Forum. 2004 Mar-Apr;31(2):313-9 [15017447.001]
  • [Cites] J Palliat Med. 2004 Apr;7(2):363-72 [15130218.001]
  • [Cites] N Engl J Med. 2004 Jun 17;350(25):2582-90 [15201415.001]
  • [Cites] Health Serv Res. 2004 Aug;39(4 Pt 1):1005-26 [15230939.001]
  • [Cites] Lancet. 1984 Apr 21;1(8382):890-4 [6143195.001]
  • [Cites] J Palliat Care. 1991 Summer;7(2):6-9 [1714502.001]
  • [Cites] J Am Geriatr Soc. 1992 Jul;40(7):697-702 [1607586.001]
  • [Cites] BMJ. 1992 Nov 28;305(6865):1317-22 [1483075.001]
  • [Cites] Psychol Rep. 1996 Dec;79(3 Pt 1):1059-69 [8969117.001]
  • [Cites] Cancer Pract. 1997 May-Jun;5(3):147-54 [9171550.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1986-96 [9586919.001]
  • [Cites] Hosp J. 1998;13(1-2):71-87 [9644394.001]
  • [Cites] Jt Comm J Qual Improv. 1998 Oct;24(10):513-7 [9801950.001]
  • [Cites] Eff Clin Pract. 1998 Aug-Sep;1(1):2-4 [10345255.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2637-44 [15728219.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2588-9 [15728223.001]
  • [Cites] J Altern Complement Med. 2005;11 Suppl 1:S7-15 [16332190.001]
  • [Cites] J Palliat Med. 2006 Feb;9(1):137-51 [16430353.001]
  • [Cites] J Pain Symptom Manage. 2006 Mar;31(3):270-84 [16563321.001]
  • [Cites] Health Promot Int. 2006 Sep;21(3):245-55 [16751630.001]
  • [Cites] Health Qual Life Outcomes. 2006;4:54 [16925807.001]
  • [Cites] Am J Manag Care. 2007 Feb;13(2):84-92 [17286528.001]
  • [Cites] J Pain Symptom Manage. 2007 Mar;33(3):238-46 [17349493.001]
  • [Cites] J Palliat Med. 2007 Apr;10(2):381-9 [17472510.001]
  • [Cites] J Clin Nurs. 2007 Mar;16(3A):95-104 [17518874.001]
  • [Cites] J Clin Oncol. 2007 Jun 10;25(17):2377-82 [17557950.001]
  • [Cites] Cancer. 2007 Jul 1;110(1):196-202 [17546575.001]
  • [Cites] J Pain Symptom Manage. 2007 Jul;34(1 Suppl):S7-S19 [17532180.001]
  • [Cites] J Pain Symptom Manage. 2007 Aug;34(2):120-5 [17583469.001]
  • [Cites] Prev Med. 2007 Oct;45(4):252-61 [17643481.001]
  • [Cites] Clin Cancer Res. 2008 Apr 1;14(7):2111-8 [18381952.001]
  • [Cites] JAMA. 2008 Apr 9;299(14):1698-709 [18398082.001]
  • [Cites] Cancer. 2008 Apr 15;112(8):1854-61 [18306393.001]
  • [Cites] BMC Psychiatry. 2008;8:60 [18647396.001]
  • [Cites] J Clin Oncol. 2008 Aug 10;26(23):3832-7 [18688049.001]
  • [CommentIn] Evid Based Nurs. 2010 Feb;13(1):9-10 [20179053.001]
  • [CommentIn] JAMA. 2009 Dec 16;302(23):2551; author reply 2551 [20009052.001]
  • (PMID = 19690306.001).
  • [ISSN] 1538-3598
  • [Journal-full-title] JAMA
  • [ISO-abbreviation] JAMA
  • [Language] ENG
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00253383
  • [Grant] United States / NCI NIH HHS / CA / R01 CA101704; United States / NCI NIH HHS / CA / P30 CA023108; United States / NINR NIH HHS / NR / R01 NR011871; United States / NINR NIH HHS / NR / T32 NR008346; United States / NINR NIH HHS / NR / T32NR008346
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS458527; NLM/ PMC3657724
  •  go-up   go-down


65. Goldberg RJ, Jang RW, Leighl NB: A willingness-to-pay study of vascular endothelial growth factor inhibitors among patients with advanced non-small cell lung cancer. J Clin Oncol; 2009 May 20;27(15_suppl):6581

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A willingness-to-pay study of vascular endothelial growth factor inhibitors among patients with advanced non-small cell lung cancer.
  • : 6581 Background: Bevacizumab, a recombinant antibody which neutralizes vascular endothelial growth factor (VEGF), has been approved for the treatment of advanced non-small cell lung cancer (NSCLC).
  • Costs of novel anticancer medications such as bevacizumab can be prohibitive for many lung cancer patients.
  • METHODS: Participants attending outpatient lung cancer clinics at a major Canadian cancer center were given information pertaining to the risks and benefits of treatment with bevacizumab and were then asked about their WTP for this agent.
  • RESULTS: 35 advanced NSCLC patients with a median age of 64.5 years and a median income of $40,000-$60,000 CAD consented to participate.
  • (2) patients understand that the government cannot fund all novel cancer therapies;.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963822.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Clayton JM, Butow PN, Tattersall MH, Devine RJ, Simpson JM, Aggarwal G, Clark KJ, Currow DC, Elliott LM, Lacey J, Lee PG, Noel MA: Randomized controlled trial of a prompt list to help advanced cancer patients and their caregivers to ask questions about prognosis and end-of-life care. J Clin Oncol; 2007 Feb 20;25(6):715-23
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized controlled trial of a prompt list to help advanced cancer patients and their caregivers to ask questions about prognosis and end-of-life care.
  • PURPOSE: To determine whether provision of a question prompt list (QPL) influences advanced cancer patients'/caregivers' questions and discussion of topics relevant to end-of-life care during consultations with a palliative care (PC) physician.
  • Consecutive eligible patients with advanced cancer referred to 15 PC physicians from nine Australian PC services were invited to participate.
  • CONCLUSION: Providing a QPL and physician endorsement of its use assists terminally ill cancer patients and their caregivers to ask questions and promotes discussion about prognosis and end-of-life issues, without creating patient anxiety or impairing satisfaction.

  • MedlinePlus Health Information. consumer health - Cancer--Living with Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Clin Pract Oncol. 2007 Oct;4(10):562-3 [17700555.001]
  • (PMID = 17308275.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


67. Kimura R, Hashiguchi S, Kawa M, Miyashita M, Sasahara T, Shirai Y, Kazuma K: Pain management and related factors in advanced cancer patients who initiated opioid therapy in an outpatient setting. Palliat Support Care; 2005 Dec;3(4):301-9
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pain management and related factors in advanced cancer patients who initiated opioid therapy in an outpatient setting.
  • OBJECTIVE: The aim of this study was to clarify the state of pain management in Japanese patients with advanced cancer who initiated opioid therapy in an outpatient setting.
  • SIGNIFICANCE OF RESULTS: Result of this study indicated insufficient pain relief at an outpatients setting with advanced cancer patients.

  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17039985.001).
  • [ISSN] 1478-9515
  • [Journal-full-title] Palliative & supportive care
  • [ISO-abbreviation] Palliat Support Care
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Analgesics, Opioid
  •  go-up   go-down


68. Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O'Dwyer PJ, Gordon MS, Novotny W, Goldwasser MA, Tohnya TM, Lum BL, Ashkenazi A, Jubb AM, Mendelson DS: Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol; 2010 Jun 10;28(17):2839-46
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer.
  • Recombinant human Apo2L/TRAIL (rhApo2L/TRAIL) has broad potential as a cancer therapy.
  • To the best of our knowledge, this is the first in-human clinical trial to assess the safety, tolerability, pharmacokinetics, and antitumor activity of multiple intravenous doses of rhApo2L/TRAIL in patients with advanced cancer.
  • PATIENTS AND METHODS: This phase I, open-label, dose-escalation study treated patients with advanced cancer with rhApo2L/TRAIL doses ranging from 0.5 to 30 mg/kg/d, with parallel dose escalation for patients without liver metastases and with normal liver function (cohort 1) and for patients with liver metastases and normal or mildly abnormal liver function (cohort 2).

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20458040.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Recombinant Proteins; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human
  •  go-up   go-down


69. Hwang I, Chi K, Do J, Lee G, Kang J, Oh S, Kwon H, Park H, Lee S, Lee S, Jang J: Clinical implication of ERCC1 overexpression in advanced biliary tract adenocarcinoma patients treated with platinum-based palliative chemotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):e22018

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical implication of ERCC1 overexpression in advanced biliary tract adenocarcinoma patients treated with platinum-based palliative chemotherapy.
  • However these studies have never been tried for biliary tract cancer.
  • The aim of this study was to evaluate the association between ERCC1 expression and treatment outcomes in advanced biliary tract adenocarcinoma patients treated with platinum-based palliative chemotherapy.
  • CONCLUSIONS: These results suggest that advanced biliary tract adenocarcinoma patients with ERCC1-negative tumors show a survival benefit from palliative chemotherapy with a platinum- containing regimen.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963197.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Soto-Cárdenas MJ, Pelayo-García G, Rodríguez-Camacho A, Segura-Fernández E, Mogollo-Galván A, Giron-Gonzalez JA: Venous thromboembolism in patients with advanced cancer under palliative care: additional risk factors, primary/secondary prophylaxis and complications observed under normal clinical practice. Palliat Med; 2008 Dec;22(8):965-8
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Venous thromboembolism in patients with advanced cancer under palliative care: additional risk factors, primary/secondary prophylaxis and complications observed under normal clinical practice.
  • Patients with advanced cancer under palliative care (PC) and with VTE, were reviewed during the three years before the study.
  • In PC patients with advanced cancer, VTE is a serious complication that conditions control of symptoms.

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18952751.001).
  • [ISSN] 1477-030X
  • [Journal-full-title] Palliative medicine
  • [ISO-abbreviation] Palliat Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Fibrinolytic Agents; 0 / Heparin, Low-Molecular-Weight
  •  go-up   go-down


71. Bush SH, Parsons HA, Palmer JL, Chacko R, Li Z, Scott C, Bruera E: Single- versus multiple-item assessment of quality of life in patients with advanced cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e20528

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single- versus multiple-item assessment of quality of life in patients with advanced cancer.
  • : e20528 Background: The main objective of palliative cancer care is to improve quality of life (QOL).
  • We assessed the performance of the Edmonton Symptom Assessment System 'feeling of well-being' item (ESAS WB) using the Functional Assessment of Cancer Therapy - General (FACT-G) instrument as a gold standard.
  • METHODS: After obtaining IRB approval, we reviewed the data from 213 advanced cancer patients who had participated in six studies from March 2006 to June 2008 and determined the level of association between baseline ESAS WB and FACT-G total score and subscale domains (Physical (Pwb), Social/Family (Swb), Emotional (Ewb), and Functional (Fwb) Well-Being) and also the 9 ESAS symptom intensity scores using Spearman correlation coefficients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961001.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Sideras K, Schaefer PL, Okuno SH, Sloan JA, Kutteh L, Fitch TR, Dakhil SR, Levitt R, Alberts SR, Morton RF, Rowland KM, Novotny PJ, Loprinzi CL: Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc; 2006 Jun;81(6):758-67
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial.
  • OBJECTIVE: To prospectively assess whether low-molecular-weight heparin (LMWH) provides a survival benefit in patients with advanced cancer.
  • PATIENTS AND METHODS: Between December 1998 and June 2001, we performed a randomized controlled study of patients with advanced cancer.

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16770976.001).
  • [ISSN] 0025-6196
  • [Journal-full-title] Mayo Clinic proceedings
  • [ISO-abbreviation] Mayo Clin. Proc.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-15083; United States / NCI NIH HHS / CA / CA-25224; United States / NCI NIH HHS / CA / CA-35101; United States / NCI NIH HHS / CA / CA-35195; United States / NCI NIH HHS / CA / CA-35431; United States / NCI NIH HHS / CA / CA-37404; United States / NCI NIH HHS / CA / CA-37417; United States / NCI NIH HHS / CA / CA-52352; United States / NCI NIH HHS / CA / CA-60276; United States / NCI NIH HHS / CA / CA-63826
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticoagulants; S79O08V79F / Dalteparin
  •  go-up   go-down


73. Sircar T, Chaudhri S, Francis A: Effect of neoadjuvant chemotherapy on oestrogen, progesterone, and HER-2 receptor expression in breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e11588

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of neoadjuvant chemotherapy on oestrogen, progesterone, and HER-2 receptor expression in breast cancer.
  • : e11588 Background: Neoadjuvant chemotherapy(NC) is used in treating locally advanced operable breast cancer.
  • METHODS: This is a retrospective study of 32 patients with locally advanced breast cancer who had NC followed by breast conservation surgery or mastectomy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964117.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Yoshimatsu K, Yokomizo H, Otani T, Osawa G, Ogawa K: Phase I study of peptide vaccine with chemotherapy in patients with unresectable colorectal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):3067

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of peptide vaccine with chemotherapy in patients with unresectable colorectal cancer.
  • : 3067 Background: RNF43 is a cancer testis antigen expressed in colorectal cancer (CRC) but not in normal organs.
  • S-1/CPT-11 chemotherapy (CT) is reported to be obtained the similar result to FOLFOX or FOLFIRI as first-line for advanced CRC.
  • These results encourage further clinical trials of peptide vaccine with standard CT for advanced CRC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962012.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Poveda A, Kaye SB, McCormack RT, Wang S, Ricci D, Broderick E, Parekh T, Lebedinsky C, Tecero JC, Monk BJ: Circulating tumor cells (CTC) in a study of relapsed/recurrent advanced ovarian cancer: An exploratory analysis in the ova-301 phase III study of pegylated liposomal doxorubicin (PLD) compared with trabectedin and PLD. J Clin Oncol; 2009 May 20;27(15_suppl):5551

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating tumor cells (CTC) in a study of relapsed/recurrent advanced ovarian cancer: An exploratory analysis in the ova-301 phase III study of pegylated liposomal doxorubicin (PLD) compared with trabectedin and PLD.
  • : 5551 Background: Circulating tumor cells (CTC) have demonstrated predictive and prognostic value among patients with metastatic breast, colorectal, and prostate cancer.
  • In a phase III study of pegylated liposomal doxorubicin (PLD) with trabectedin (T) vs PLD for relapsed ovarian cancer, we assessed the affect of CTCs on progression free survival, (PFS) and overall survival (OS).
  • CONCLUSIONS: Results from this study indicate that although CTC detection in blood from relapsed recurrent ovarian cancer patients is relatively low, elevated numbers of CTCs imparts an unfavorable prognosis for patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962543.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Bowman KF, Rose JH, Radziewicz RM, O'Toole EE, Berila RA: Family caregiver engagement in a coping and communication support intervention tailored to advanced cancer patients and families. Cancer Nurs; 2009 Jan-Feb;32(1):73-81
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Family caregiver engagement in a coping and communication support intervention tailored to advanced cancer patients and families.
  • We describe family caregiver (FCG) participation in a tailored coping and communication support intervention for advanced cancer patients and families.
  • Findings will guide modification and dissemination of this intervention primarily in cancer clinics for the underserved.

  • MedlinePlus Health Information. consumer health - Caregivers.
  • MedlinePlus Health Information. consumer health - Family Issues.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19104204.001).
  • [ISSN] 1538-9804
  • [Journal-full-title] Cancer nursing
  • [ISO-abbreviation] Cancer Nurs
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA102828; United States / NCI NIH HHS / CA / R01-CA10282
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


77. Dewey A, Dean T: Assessment and monitoring of nutritional status in patients with advanced cancer: part 1. Int J Palliat Nurs; 2007 Jun;13(6):258-65
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment and monitoring of nutritional status in patients with advanced cancer: part 1.
  • Using a qualitative approach, this study set out to explore nurses' management of patients with advanced cancer, weight loss and eating-associated problems.
  • Extreme weight loss is commonly seen in patients with incurable solid tumour cancer and, to date, it has proved difficult to manage successfully.
  • Many nurses were reluctant to initiate conversations with cancer patients about weight loss, but instead waited for patients and relatives to raise their concerns.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17851381.001).
  • [ISSN] 1357-6321
  • [Journal-full-title] International journal of palliative nursing
  • [ISO-abbreviation] Int J Palliat Nurs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


78. Rowlands J, Noble S: How does the environment impact on the quality of life of advanced cancer patients? A qualitative study with implications for ward design. Palliat Med; 2008 Sep;22(6):768-74

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How does the environment impact on the quality of life of advanced cancer patients? A qualitative study with implications for ward design.
  • The aim of this study is to explore the views of patients with advanced cancer on the effect the ward environment has on their overall well-being.
  • Semi-structured interviews exploring the experiences of 12 inpatients at a regional cancer centre were recorded and transcribed verbatim.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18715977.001).
  • [ISSN] 1477-030X
  • [Journal-full-title] Palliative medicine
  • [ISO-abbreviation] Palliat Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


79. Bausewein C, Booth S, Gysels M, Kühnbach R, Haberland B, Higginson IJ: Individual breathlessness trajectories do not match summary trajectories in advanced cancer and chronic obstructive pulmonary disease: results from a longitudinal study. Palliat Med; 2010 Dec;24(8):777-86
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Individual breathlessness trajectories do not match summary trajectories in advanced cancer and chronic obstructive pulmonary disease: results from a longitudinal study.
  • Breathlessness is a distressing symptom in advanced disease.
  • This study aimed to describe and compare the summary and individual trajectories of breathlessness and overall symptom burden over time and towards the end of life following patients with advanced cancer or severe chronic obstructive pulmonary disease (COPD) in inpatient and outpatient health care settings in Germany.
  • Forty-nine cancer and 60 COPD patients were included.
  • Thirty out of the 49 cancer and 6/60 COPD patients died, 7/49 cancer and 20/60 COPD patients dropped out due to physical deterioration or questionnaire fatigue.
  • In cancer patients, breathlessness increased towards death.
  • Twenty-one cancer and 43 COPD patients provided data for individual breathlessness trajectories.


80. Fêde AB, da Costa Miranda V, Martins FD, Magalhães NP, Schaffhausser HL, Riechelmann RP, Del Giglio A: Doctor, how long? J Clin Oncol; 2009 May 20;27(15_suppl):e20653

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e20653 Background: In practice it is common to start terminal sedation for patients with advanced cancer who develop physical discomfort not amenable to be treated by other means.
  • We aimed at quantifying the average survival time of terminal cancer patients once sedation was started until death and identify potential variables that may influence their survival time on sedation.
  • METHODS: This is a retrospective cohort analysis of all consecutive terminal cancer patients who died after starting terminal sedation at public tertiary brazilian Hospital during 2 years (January 2005 to January 2007).
  • RESULTS: 532 cancer patients died in Hospital Estadual Mário Covas during this period and 181 out of them who received terminal sedation were included in this analysis.
  • CONCLUSIONS: Sedated, terminal cancer patients usually live about one day.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961628.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Smith M, Kutner J, Hemphill L, Yamashita T, Felton S: Developing treatment and control conditions in a clinical trial of massage therapy for advanced cancer. J Soc Integr Oncol; 2007;5(4):139-46
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Developing treatment and control conditions in a clinical trial of massage therapy for advanced cancer.
  • The purpose of this article is to describe the challenges faced by a research team in developing treatment and control conditions in a study of the efficacy of massage therapy for advanced cancer.

  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19087757.001).
  • [ISSN] 1715-894X
  • [Journal-full-title] Journal of the Society for Integrative Oncology
  • [ISO-abbreviation] J Soc Integr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


82. Walsh D, Perin ML, McIver B: Parenteral morphine prescribing patterns among inpatients with pain from advanced cancer: a prospective survey of intravenous and subcutaneous use. Am J Hosp Palliat Care; 2006 Oct-Nov;23(5):353-9
Hazardous Substances Data Bank. MORPHINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parenteral morphine prescribing patterns among inpatients with pain from advanced cancer: a prospective survey of intravenous and subcutaneous use.
  • Prescribing patterns for parenteral morphine for symptom control in advanced cancer were studied in 50 consecutive hospital admissions (27 men, 23 women, median age, 62 years).
  • These patterns of parenteral morphine application reflect the complexity of the challenge presented by the various cancer pain syndromes.

  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17060302.001).
  • [ISSN] 1049-9091
  • [Journal-full-title] The American journal of hospice & palliative care
  • [ISO-abbreviation] Am J Hosp Palliat Care
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 76I7G6D29C / Morphine
  •  go-up   go-down


83. Dy SM, Apostol CC: Evidence-based approaches to other symptoms in advanced cancer. Cancer J; 2010 Sep-Oct;16(5):507-13
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence-based approaches to other symptoms in advanced cancer.
  • Dyspnea, nausea and vomiting, anorexia, fatigue, and sleep disturbances are common and distressing in advanced cancer.
  • The strongest evidence supports metoclopramide for cancer-related nausea and octreotide for bowel obstruction.
  • For insomnia, evidence supports cognitive-behavioral therapy in cancer; no sleep agents have superior effectiveness.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20890148.001).
  • [ISSN] 1540-336X
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  •  go-up   go-down


84. Koffman J, Morgan M, Edmonds P, Speck P, Higginson I: Cultural meanings of pain: a qualitative study of Black Caribbean and White British patients with advanced cancer. Palliat Med; 2008 Jun;22(4):350-9
MedlinePlus Health Information. consumer health - Cancer--Living with Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cultural meanings of pain: a qualitative study of Black Caribbean and White British patients with advanced cancer.
  • Pain is a common cancer-related symptom, but little research has been conducted that explores the meanings of this symptom across different ethnic groups.
  • This study involved qualitative interviews to explore and compare the meanings of pain among 26 Black Caribbean and 19 White patients with advanced cancer.
  • A total of 23/26 Black Caribbean and 15/19 White patients reported cancer-related pain.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18541639.001).
  • [ISSN] 0269-2163
  • [Journal-full-title] Palliative medicine
  • [ISO-abbreviation] Palliat Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


85. Radziewicz RM, Rose JH, Bowman KF, Berila RA, O'Toole EE, Given B: Establishing treatment fidelity in a coping and communication support telephone intervention for aging patients with advanced cancer and their family caregivers. Cancer Nurs; 2009 May-Jun;32(3):193-202
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishing treatment fidelity in a coping and communication support telephone intervention for aging patients with advanced cancer and their family caregivers.
  • A randomized controlled trial of a nurse-delivered coping and communication support (CCS) intervention tailored to the preferences of middle-aged and older patients with advanced cancer and their family caregivers is tested for its value in improving outcomes for quality cancer care.

  • MedlinePlus Health Information. consumer health - Cancer--Living with Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19295420.001).
  • [ISSN] 1538-9804
  • [Journal-full-title] Cancer nursing
  • [ISO-abbreviation] Cancer Nurs
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA102828; United States / NCI NIH HHS / CA / R01-CA10282
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Number-of-references] 28
  •  go-up   go-down


86. Oh S, Kim S, Kwon H, Kim H, Hwang I, Kang J, Lee S, Lee J, Kang W: Leptomeningeal carcinomatosis of gastric cancer: Multicenter retrospective analysis of 54 cases. J Clin Oncol; 2009 May 20;27(15_suppl):e15658

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leptomeningeal carcinomatosis of gastric cancer: Multicenter retrospective analysis of 54 cases.
  • : e15658 Background: Leptomeningeal carcinomatosis occurs in approximately 5% of patients with cancer.
  • The most common cancers involving the leptomeninges are breast and lung cancer.
  • The majority of patients had advanced disease at the initial diagnosis of gastric cancer.
  • The clinical or pathologic TNM stages of the primary gastric cancer were IV in 38 patients (70%).
  • Clinically, initial advanced stage was predictive value of poor prognosis (P=0.009).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962774.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Loehr M, Bodoky G, Fölsch U, Märten A, Karrasch M, Lilla C, Meyer I, Osinsky D, Szanto J, Lutz M: Cationic liposomal paclitaxel in combination with gemcitabine in patients with advanced pancreatic cancer: A phase II trial. J Clin Oncol; 2009 May 20;27(15_suppl):4526

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cationic liposomal paclitaxel in combination with gemcitabine in patients with advanced pancreatic cancer: A phase II trial.
  • We present safety and efficacy data of a randomized, controlled phase II trial in pancreatic cancer (PC).
  • METHODS: 200 patients with advanced PC were randomized to 1<sup>st</sup> line treatment with weekly gemcitabine (GEM: 1000 mg/m<sup>2</sup>) and twice weekly infusions of EndoTAG-1 (E) at 3 different dose levels (E<sub>low</sub>: 11 mg/m<sup>2</sup>, E<sub>med</sub>: 22 mg/m<sup>2</sup>, E<sub>high</sub>: 44 mg/m<sup>2</sup>) or GEM monotherapy.
  • CONCLUSIONS: This phase II trial indicates a considerable survival benefit for patients with advanced PC receiving EndoTAG-1 in combination with gemcitabine and a favourable safety profile warranting further development of EndoTAG-1 in this indication.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962719.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Moss AH, Lunney JR, Culp S, Auber M, Kurian S, Rogers J, Dower J, Abraham J: Prognostic significance of the "surprise" question in cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):9588

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of the "surprise" question in cancer patients.
  • : 9588 Background: In patients with advanced cancer, failure to accurately estimate and communicate prognoses can lead to overly aggressive care at the end of life with less attention to important palliative care issues such as pain and symptom management and patients' values and goals for care.
  • It has not been previously tested in cancer patients.
  • The purposes of this study were to determine the feasibility and outcomes of the use of the "surprise" question in a cancer center population.
  • METHODS: Between July and November 2007, oncologists prospectively classified consecutive breast, lung, and colon cancer patients being seen at the Mary Babb Randolph Cancer Center of West Virginia University into "Yes" and "No" groups based on the surprise question.
  • Patients were followed and their status at the end of one year-alive or dead-was determined along with patient demographics, type of cancer, and stage at presentation.
  • The surprise question 'No' response was more predictive of patient death than stage of cancer, cancer type, or age (hazard ratio 7.53, P value <.001).
  • CONCLUSIONS: We conclude that the surprise question is a simple, feasible, and effective tool to identify cancer patients with the worst prognoses who should receive the highest priority for palliative care interventions, particularly advance care planning.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963736.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Schellens JH, Leijen S, Shapiro GI, Pavlick AC, Tibes R, O'Day SJ, Demuth T, Viscusi J, Xu Y, Oza AM: A phase I and pharmacological study of MK-1775, a Wee1 tyrosine kinase inhibitor, in both monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):3510

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I and pharmacological study of MK-1775, a Wee1 tyrosine kinase inhibitor, in both monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors.
  • G2 checkpoint abrogation may therefore sensitize p53 deficient tumor cells to anti-cancer agents.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961310.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Lee JJ, Lee JJ: A phase II study of an herbal decoction that includes Astragali radix for cancer-associated anorexia in patients with advanced cancer. Integr Cancer Ther; 2010 Mar;9(1):24-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of an herbal decoction that includes Astragali radix for cancer-associated anorexia in patients with advanced cancer.
  • HYPOTHESIS: Anorexia and cancer cachexia produce significant loss of adipose tissue and muscle mass and eventually reduce survival in cancer patients.
  • STUDY DESIGN: This phase II study was conducted to assess the efficacy and the safety of an herbal decoction with Astragali radix in patients with anorexia in advanced cancer.
  • METHODS: All patients with histologic evidence of an incurable malignancy had a weight loss of at least 5% during the preceding 6 months and a patient-estimated severe anorexia.The herbal decoction was administered 30 minutes after meals, three times a day for 3 weeks.The score of appetite, body weight, the cytokines, IL-1beta, IL-6, TNF-alpha, and anthropometric measurements were assessed.
  • This herbal decoction shows some potential for management of cancer-related anorexia.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LACTIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20150220.001).
  • [ISSN] 1552-695X
  • [Journal-full-title] Integrative cancer therapies
  • [ISO-abbreviation] Integr Cancer Ther
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Astragali compound; 0 / Cytokines; 0 / Drugs, Chinese Herbal; 33X04XA5AT / Lactic Acid
  •  go-up   go-down


91. Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, MacGregore-Cortelli B, Tong W, Secrist JP, Schwartz L, Richardson S, Chu E, Olgac S, Marks PA, Scher H, Richon VM: Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol; 2005 Jun 10;23(17):3923-31
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.
  • PURPOSE: To determine the safety, dosing schedules, pharmacokinetic profile, and biologic effect of orally administered histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in patients with advanced cancer.

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Vorinostat .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2003 Jan 10;112(1):11-7 [12526789.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] FEBS Lett. 2001 Jun 22;499(3):199-204 [11423116.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jul;86(7):3430-5 [11443220.001]
  • [Cites] Gene Expr. 1996;5(4-5):245-53 [8723390.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2860-5 [11854457.001]
  • [Cites] Am J Respir Cell Mol Biol. 2001 Nov;25(5):562-8 [11713097.001]
  • [Cites] J Clin Oncol. 1990 May;8(5):813-9 [2185339.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] Adv Cancer Res. 2004;91:137-68 [15327890.001]
  • [Cites] Curr Opin Genet Dev. 2002 Apr;12(2):198-209 [11893494.001]
  • [Cites] Nat Genet. 2002 Jun;31(2):141-9 [11992124.001]
  • [Cites] Genome Biol. 2002;3(5):reviews0006 [12049668.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11700-5 [12189205.001]
  • [Cites] Nat Genet. 2002 Dec;32(4):606-13 [12402037.001]
  • [Cites] Blood. 2003 Apr 15;101(8):2914-23 [12515714.001]
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3578-88 [14506144.001]
  • [Cites] Endocrinology. 2004 Jun;145(6):2865-75 [14976143.001]
  • (PMID = 15897550.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA092629; United States / NCI NIH HHS / CA / R21 CA096228; United States / NCI NIH HHS / CA / CA96228-0
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Histone Deacetylase Inhibitors; 0 / Hydroxamic Acids; 58IFB293JI / vorinostat
  • [Other-IDs] NLM/ NIHMS18169; NLM/ PMC1855284
  •  go-up   go-down


92. Nekolaichuk CL, Fainsinger RL, Lawlor PG: A validation study of a pain classification system for advanced cancer patients using content experts: the Edmonton Classification System for Cancer Pain. Palliat Med; 2005 Sep;19(6):466-76
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A validation study of a pain classification system for advanced cancer patients using content experts: the Edmonton Classification System for Cancer Pain.
  • The purpose of this study was to gather construct validity evidence for a pain classification system for advanced cancer patients using content experts.
  • To reflect its intended use as a classification system, the name of the instrument was changed to the Edmonton Classification System for Cancer Pain (ECS-CP).

  • MedlinePlus Health Information. consumer health - Pain.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16218159.001).
  • [ISSN] 0269-2163
  • [Journal-full-title] Palliative medicine
  • [ISO-abbreviation] Palliat Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] England
  •  go-up   go-down


93. Briasoulis E, Golfinopoulos V, Karina M, Papakostas P, Pavlidis N, Fountzilas G: Phase I trial of weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: a Hellenic Cooperative Oncology Group Study. Anticancer Drugs; 2010 Sep;21(8):785-9
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: a Hellenic Cooperative Oncology Group Study.
  • This trial aimed to define a recommended safe dose (RSD) of weekly paclitaxel and irinotecan combined with carboplatin in patients with advanced cancer.
  • Patients with advanced cancer were eligible for this trial.
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Neoplasm Staging. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20647930.001).
  • [ISSN] 1473-5741
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 7673326042 / irinotecan; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


94. Agar M, To T, Plummer J, Abernethy A, Currow D: Anti-cholinergic load, health care utilization, and survival in people with advanced cancer: a pilot study. J Palliat Med; 2010 Jun;13(6):745-52
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-cholinergic load, health care utilization, and survival in people with advanced cancer: a pilot study.
  • Anti-cholinergic load associated with medication increases as death approaches in those with advanced cancer, yet little is known about associated adverse outcomes in this setting.
  • METHODS: A substudy of 112 participants in a randomised control trial who had cancer and an Australia modified Karnofsky Performance Scale (AKPS) score (AKPS) of 60 or above, explored survival and health service utilisation; with anti-cholinergic load calculated using the Clinician Rated Anti-cholinergic Scale (modified version) longitudinally to death.
  • [MeSH-major] Cholinergic Antagonists / therapeutic use. Health Services / utilization. Neoplasm Staging. Neoplasms / drug therapy. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20597708.001).
  • [ISSN] 1557-7740
  • [Journal-full-title] Journal of palliative medicine
  • [ISO-abbreviation] J Palliat Med
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cholinergic Antagonists
  •  go-up   go-down


95. Curtis JR, Engelberg R, Young JP, Vig LK, Reinke LF, Wenrich MD, McGrath B, McCown E, Back AL: An approach to understanding the interaction of hope and desire for explicit prognostic information among individuals with severe chronic obstructive pulmonary disease or advanced cancer. J Palliat Med; 2008 May;11(4):610-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An approach to understanding the interaction of hope and desire for explicit prognostic information among individuals with severe chronic obstructive pulmonary disease or advanced cancer.
  • METHODS: We conducted in-depth longitudinal qualitative interviews with patients with either advanced cancer or severe chronic obstructive pulmonary disease (COPD), along with their family, physicians, and nurses.


96. Hishinuma S, Ogata Y, Tomikawa M, Ozawa I: Stomach-preserving distal pancreatectomy with combined resection of the celiac artery: radical procedure for locally advanced cancer of the pancreatic body. J Gastrointest Surg; 2007 Jun;11(6):743-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stomach-preserving distal pancreatectomy with combined resection of the celiac artery: radical procedure for locally advanced cancer of the pancreatic body.
  • To enhance the resectability of cancer of the pancreatic body, a new surgical technique should be developed.
  • Of 25 patients with cancer of the pancreatic body who underwent distal pancreatectomy with curative intent, seven with cancer invasion around the celiac artery underwent stomach-preserving distal pancreatectomy with combined resection of the celiac artery.
  • The present study suggests that this surgical procedure is a rational approach to locally advanced pancreatic body cancer invading around the celiac artery.
  • In view of the feasibility of this procedure, it can also be adopted for less advanced cancer of the pancreatic body to enhance local control and survival.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatobiliary Pancreat Dis Int. 2003 Nov;2(4):622-5 [14627533.001]
  • [Cites] Surg Today. 2003;33(11):873-8 [14605963.001]
  • [Cites] Cancer. 1996 Jun 1;77(11):2240-5 [8635090.001]
  • [Cites] Ann Surg. 1984 Apr;199(4):418-25 [6712317.001]
  • [Cites] Cancer. 1953 Jul;6(4):704-7 [13059764.001]
  • [Cites] Am J Surg. 1992 Jul;164(1):26-31 [1378243.001]
  • [Cites] Langenbecks Arch Surg. 2003 Apr;388(2):101-6 [12684805.001]
  • [Cites] Am J Surg. 2006 Sep;192(3):330-5 [16920427.001]
  • [Cites] J Gastrointest Surg. 2006 Apr;10(4):511-8 [16627216.001]
  • [Cites] Hepatogastroenterology. 2005 Jul-Aug;52(64):1090-1 [16001636.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2005;12 (1):55-60 [15754101.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2005;12(3):235-42 [15995813.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(2):183-7 [10982611.001]
  • [Cites] J Gastrointest Surg. 2003 Dec;7(8):946-52; discussion 952 [14675703.001]
  • [Cites] J Gastrointest Surg. 2005 Apr;9(4):503-7 [15797231.001]
  • [Cites] Hepatogastroenterology. 1997 Mar-Apr;44(14):387-93 [9164507.001]
  • [Cites] Int J Pancreatol. 1997 Aug;22(1):15-21 [9387020.001]
  • [Cites] Hepatogastroenterology. 1999 Jul-Aug;46(28):2628-30 [10522054.001]
  • [Cites] J Gastrointest Surg. 2005 Sep-Oct;9(7):922-7 [16137585.001]
  • (PMID = 17417712.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Rustin GJ, Shreeves G, Nathan PD, Gaya A, Ganesan TS, Wang D, Boxall J, Poupard L, Chaplin DJ, Stratford MR, Balkissoon J, Zweifel M: A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer. Br J Cancer; 2010 Apr 27;102(9):1355-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer.
  • METHODS: Patients with advanced cancer refractory to standard therapy were treated with CA4P as a 10-min infusion, 20 h before carboplatin, paclitaxel, or paclitaxel, followed by carboplatin.
  • Responses were seen in 10 of 46 (22%) patients with ovarian, oesophageal, small-cell lung cancer, and melanoma.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Vascul Pharmacol. 2009 Nov-Dec;51(5-6):337-43 [19737629.001]
  • [Cites] Eur J Cancer. 2000 Sep;36(14):1833-43 [10974632.001]
  • [Cites] Radiother Oncol. 2001 Aug;60(2):155-61 [11439210.001]
  • [Cites] Int J Cancer. 2002 May 1;99(1):1-6 [11948484.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3408-16 [12067983.001]
  • [Cites] Br J Cancer. 2003 Apr 22;88(8):1160-7 [12698178.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10 Suppl):187s-193s [12743133.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2815-22 [12807934.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2823-30 [12807935.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2831-42 [12807936.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4428-38 [14645433.001]
  • [Cites] Eur J Cancer. 2004 Jan;40(2):284-90 [14728944.001]
  • [Cites] Anticancer Drugs. 1993 Feb;4(1):19-25 [8457709.001]
  • [Cites] Cancer Res. 1999 Apr 1;59(7):1626-34 [10197639.001]
  • [Cites] J Natl Cancer Inst. 2004 Nov 17;96(22):1682-91 [15547181.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1527-33 [15746056.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jul-Aug;16(4):1557-64 [16884365.001]
  • [Cites] Science. 2006 Sep 22;313(5794):1785-7 [16990548.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):211-7 [17448875.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2007 Aug;19(6):443-56 [17459681.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Aug;92(8):2902-9 [17550961.001]
  • [Cites] Anticancer Res. 2000 Jan-Feb;20(1A):229-33 [10769660.001]
  • (PMID = 20389300.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Stilbenes; BG3F62OND5 / Carboplatin; I5590ES2QZ / fosbretabulin; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ PMC2865759
  •  go-up   go-down


98. Koffman J, Morgan M, Edmonds P, Speck P, Higginson IJ: Vulnerability in palliative care research: findings from a qualitative study of black Caribbean and white British patients with advanced cancer. J Med Ethics; 2009 Jul;35(7):440-4
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vulnerability in palliative care research: findings from a qualitative study of black Caribbean and white British patients with advanced cancer.
  • AIM: To examine issues of vulnerability in cancer and palliative care research obtained through qualitative interviews.
  • METHOD: Secondary analysis of qualitative data from 26 black Caribbean and 19 white British patients with advanced cancer.

  • MedlinePlus Health Information. consumer health - Cancer--Living with Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19567695.001).
  • [ISSN] 1473-4257
  • [Journal-full-title] Journal of medical ethics
  • [ISO-abbreviation] J Med Ethics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


99. Adjei AA, Cohen RB, Kurzrock R, Gordon GS, Hangauer D, Dyster L, Fetterly G, Barrientes S, Hong DS, Naing A: Results of a phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket directed SRC inhibitor, in patients with advanced malignancies. J Clin Oncol; 2009 May 20;27(15_suppl):3511

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket directed SRC inhibitor, in patients with advanced malignancies.
  • 7 pts had prolonged stable disease for 4 months or longer including 2 pts with papillary thyroid carcinoma, 2 with carcinoid, and 1 each with prostate, pancreas, and head and neck cancer.
  • Both the prostate and pancreatic cancer pts had dramatic decreases in their biomarkers (PSA went from 205 ng/ml to 39 ng/ml, and CA19-9 went from 38,838 U/ml to 267 U/ml, respectively).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961307.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Monk B, Mas L, Zarba JJ, Oaknin A, Tarpin C, Termrungruanglert W, Alber JA, Ding J, Stutts NW, Pandite LN: A randomized phase II study: Pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L+P) in advanced and recurrent cervical cancer (CC). J Clin Oncol; 2009 May 20;27(15_suppl):5520

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized phase II study: Pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L+P) in advanced and recurrent cervical cancer (CC).
  • P and L both demonstrated a favorable toxicity profile in pts with advanced and recurrent CC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962484.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement